Page last updated: 2024-08-23

selegiline and Idiopathic Parkinson Disease

selegiline has been researched along with Idiopathic Parkinson Disease in 737 studies

Research

Studies (737)

Timeframe	Studies, this research(%)	All Research%
pre-1990	144 (19.54)	18.7374
1990's	344 (46.68)	18.2507
2000's	139 (18.86)	29.6817
2010's	88 (11.94)	24.3611
2020's	22 (2.99)	2.80

Authors

Authors	Studies
Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V	1
Abe, K; Horiguchi, Y; Kitabatake, M; Mohri, K; Nagai, J; Ogawa, K; Taguchi, K; Tsuchiya, Y; Yokoyama, T	1
Matos, MJ; Orallo, F; Picciau, C; Santana, L; Uriarte, E; Viña, D	1
Camins, A; Camps, P; Duque, MD; Kelly, JM; López-Querol, M; Prathalingam, SR; Sureda, FX; Torres, E; Valverde, E; Vázquez, S	1
Alcaro, S; Bolasco, A; Cardia, MC; Distinto, S; Gaspari, M; Kirchmair, J; Maccioni, E; Markt, P; Meleddu, R; Ortuso, F; Sanna, ML; Secci, D; Wolber, G; Yáñez, M	1
Legoabe, LJ; Petzer, A; Petzer, JP	1
Choo, H; Choo, IH; Jo, S; Keum, G; Kim, J; Kim, T; Lee, CJ; Lee, J; Lim, EJ; Min, SJ; Moon, B; Nam, G; Park, HR; Park, KD; Yeom, M	1
Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R	1
Amar, M; Ferrié, L; Figadère, B; Harfouche, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Séon-Méniel, B; Sepulveda-Diaz, JE	1
Petzer, A; Petzer, JP; Terre'Blanche, G; Van der Walt, MM	1
Aktumsek, A; Alcaro, S; Bagetta, D; Carradori, S; De Monte, C; De Vita, D; Guglielmi, P; Ortuso, F; Petzer, A; Petzer, JP; Secci, D; Zengin, G	1
Bahn, YS; Choi, JW; Han, G; Jang, BK; Kim, HJ; Kim, S; Lee, YR; Lee, YS; Pae, AN; Park, JH; Park, KD; Shin, SJ; Yeon, SK	1
Legoabe, LJ; Petzer, A; Petzer, JP; Qhobosheane, MA	1
Bao, XQ; Gao, F; Li, L; Tao, D; Wang, L; Wang, Y; Yang, BB; Zhang, D	1
Legoabe, LJ; Meiring, L; Petzer, A; Petzer, JP	1
Danış, Ö; Elzien Alamin Ali, H; Odabaş, Z; Ozalp, L	1
Agnieszka, W; Małgorzata, K; Paweł, P	1
Hall, J; Johnson, L; Mason, D; O'Bryant, SE; Petersen, M; Zhang, F	1
Chen, SD; Jenner, P; Tan, YY	1
Chew, ZX; Chye, SM; Koh, RY; Lim, CL; Ling, APK; Ng, KY	1
Jost, WH	1
Chen, J; Cheng, X; Han, Y; Jin, H; Li, J; Liu, C; Luo, W; Mao, C; Meng, M; Miao, H; Xiong, K; Zhang, J; Zhu, X	1
Chen, J; Chen, Y; Yu, H; Zhao, J; Zheng, Y; Zhu, J	1
Chou, SC; Tai, CH; Tseng, SH	1
Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M	1
Iguchi, Y; Kitagawa, T; Komatsu, T; Maku, T; Mimori, M; Mitsumura, H; Murakami, H; Okumura, M; Omoto, S; Ozawa, M; Sakai, K; Sato, T; Shiraishi, T; Takatsu, H; Umehara, T	1
Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H	1
Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R	1
Fay-Karmon, T; Gutman-Sharabi, N; Halperin, R; Khashab, R; Landau, R; Leibowitz, A; Shabtai, Z; Sharabi, Y	1
Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M	1
Riederer, P; Szökő, É; Tábi, T; Vécsei, L; Youdim, MB	1
Maruyama, W; Naoi, M; Shamoto-Nagai, M	1
Parambi, DGT	1
Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF	1
Bianchi, ML; Carimati, F; Gallazzi, M; Mauri, M; Princiotta Cariddi, L; Rebecchi, V; Riboldazzi, G; Versino, M	1
Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C	1
Canesi, M; Cereda, E; Cilia, R; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, AL	1
Magyar, K; Riederer, P; Szökő, É; Tábi, T; Vécsei, L	1
Mishra, KP; Niranjan, R; Thakur, AK	1
Auinger, P; Christine, CW; Green, R; Joslin, A; Yelpaala, Y	1
Müller, T; Riederer, P	1
Rukmangathen, R; Yalavarthi, PR; Yallamalli, IM	1
Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K	1
Binde, CD; Gåsemyr, J; Klemp, M; Natvig, B; Tvete, IF	1
Alborghetti, M; Nicoletti, F	1
Bajaj, A; Gaud, R; Sridhar, V; Wairkar, S	1
Deshmukh, R; Kumar, A; Mishra, N; Sharma, R; Sharma, S	1
Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR	1
Chen, XB; Jiang, DQ; Jiang, LL; Li, MX; Zhou, XW	1
Sheehan, J; Thorpe, M; Wilson, L	1
Magyar, K; Szökő, E; Tábi, T; Vécsei, L	1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ	1
Auinger, P; Cain, KC; Ginghina, C; Kang, UJ; Liu, C; Mattison, HA; McDermott, MP; Shi, M; Stewart, T; Zhang, J	1
Inaba-Hasegawa, K; Maruyama, W; Naoi, M	1
Miklya, I	4
Bai, Y; Cai, D; Zhao, Q	1
Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC	1
Luo, S	1
Alamri, Y; Anderson, TJ; Dalrymple-Alford, JC; Espiner, EA; Prickett, TC	1
Augustine, EF; Auinger, P; Constantinescu, R; Elm, J; Khadim, L; Kieburtz, K; Sharma, S	1
Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K	1
Godse, RD; Nair, HA; Wasnik, MN	1
Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Stewart, T; Zhang, J	1
Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH	1
Luo, S; Wang, J	1
Göltl, P; Hafenscher, F; Miklya, I; Pencz, N	1
Marconi, S; Zwingers, T	1
Ellmén, J; Kieburtz, K; Kuoppamäki, M; Vahteristo, M	1
Müller, T	1
Friede, M; Jost, WH; Schnitker, J	1
Becker, S; Eisbach, SE; Fernández, CO; Fonseca-Ornelas, L; Giller, K; Outeiro, TF; Paulat, M; Zweckstetter, M	1
Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Zhang, J	1
Hasegawa, T	1
Doyu, M; Ibi, T; Niwa, J; Taguchi, S	1
Cheng, X; Li, S; Liu, B; Lv, C; Ma, Y; Mao, W; Sun, J; Zhang, J	1
Buda, S; Degli Esposti, L; Nobili, F; Piccinni, C; Sangiorgi, D	1
Chen, G; Luo, S	1
Asgharnejad, M; Bauer, L; Boroojerdi, B; Giladi, N; Grieger, F	1
Hattori, N; Mori, H; Yoritaka, A	1
Belvisi, D; Berardelli, A; Bologna, M; Colella, D; Fabbrini, G; Fasano, A; Leodori, G; Paparella, G; Stirpe, P	1
Ali, J; Baboota, S; Kumar, S	1
Cheng, X; Li, S; Liu, B; Liu, Y; Lv, C; Ma, Y; Mao, W; Sun, J; Zhang, J	1
Grünblatt, E; Müller, T; Riederer, P	1
Ben-Shlomo, Y; Evans, A; Head, J; Katzenschlager, R; Lees, AJ; Schrag, A	1
Chetsawang, B; Ebadi, M; Govitrapong, P; Kooncumchoo, P	1
Aoki, Y; Endo, S; Fujino, Y; Fujita, Y; Inoue, Y; Niitsu, H; Onodera, M; Takahashi, K; Takei, M	1
Jost, WH; Klasser, M; Reichmann, H	1
Aasly, JO; Beiske, AG; Bekkelund, SI; Dietrichs, E; Larsen, JP; Tysnes, OB; Vilming, ST	1
Löhle, M; Storch, A	1
Klivényi, P; Rákóczi, K; Vécsei, L	1
Pirtosek, Z	1
Lewitt, PA	7
Amit, T; Drigues, N; Sagi, Y; Weinreb, O; Youdim, MB	1
Dayoub, EJ; Dorsey, ER; George, B; Holloway, RG; Saubermann, LA; Thompson, JP	1
Castrén, E; Gyárfás, T; Knuuttila, J; Lindholm, P; Rantamäki, T	1
Caslake, R; Counsell, C; Ives, N; Macleod, A; Stowe, R	1
Anderson, SW; Auinger, P; Chou, KL; Como, PG; Growdon, JC; Litvan, I; Marder, KS; McDermott, MP; Uc, EY	1
Eberly, SW; Fahn, S; Hyson, C; Lang, AE; Marras, C; Oakes, D; Schwid, SR; Shoulson, I	1
Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U	1
Adar, L; Goren, T; Sasson, N; Weiss, YM	1
Schneemilch, C	1
Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB	1
Bosco, D; Bosco, F; Consoli, A; Plastino, M; Rotondo, A	1
Williams, R	1
Bornholdt, J; Clausen, RP; Felding, J; Kristensen, JL	1
Imamura, K; Nagatsu, T; Okayasu, N	2
Landau, WM	3
Davidson, A; Hunter, C; Isaacson, SH; Ondo, WG; Silver, DE; Stewart, RM; Tetrud, JW	1
Au, WL; Li, SC; Luo, N; Seah, SH; Tan, LC; Wee, HL; Zhao, YJ	1
Knudsen Gerber, DS	1
Chairangsaris, P; Chinvarun, Y; Nidhinandana, S; Orrawanhanothai, P; Sithinamsuwan, P; Suphakasem, S; Suwantamee, J; Thithum, K; Udommongkol, C; Wongmek, W	1
Keller, D	1
Auinger, P; LeWitt, P; Lu, M; Schultz, L	1
Ascherio, A; Auinger, P; Chen, H; Eberly, S; Huang, X; Mailman, R; Oakes, D; Schwarzschild, M	1
Magyar, K	1
Holford, NH; Nutt, JG; Vu, TC	2
Borges, F; Cadoni, E; Ferino, G; Laguna, R; Matos, MJ; Santana, L; Uriarte, E; Viña, D	1
Chen, R; Chuang, R; Hamani, C; Hodaie, M; Lim, SY; Lozano, AM; Mazzella, F; Moro, E; Neagu, B; Saha, U; Steeves, T; Tsang, EW	1
Munhoz, RP; Teive, HA; Zavala, JA	1
Keränen, T; Kuusisto, H; Luukkaala, T; Mattila, T	1
Dimpfel, W; Hoffmann, JA; Müller, T; Oehlwein, C	1
Djaldetti, R; Melamed, E; Ziv, I	1
Fann, JR	1
Fahn, S; Kieburtz, K; Lang, A; Langston, JW; LeWitt, P; Oakes, D; Olanow, CW; Penney, JB; Rudolph, A; Shoulson, I; Tanner, C	1
Efimenko, VN; Evtushenko, SK; Kazarian, NE; Lutskiĭ, IS	1
Brekke, L; Ebadi, M; Sangchot, P; Sharma, S; Shavali, S	1
Gille, G; Müller, T; Przuntek, H; Reichmann, H; Riederer, P; Riess, O; Schwartz, A; Schwarz, J; Vogt, T	1
Kondo, T; Mizuno, Y; Okuma, Y; Takubo, H; Yokochi, F	1
Bhattacharya, KF; Kaufmann, H; Nouri, S; Olanow, CW; Yahr, MD	1
Vécsei, L	1
Agid, Y; Olanow, CW; Schapira, AH	1
Knoll, B; Knoll, J; Miklya, I	1
Iida, Y; Saji, H	1
Chalmers-Redman, R; Tatton, N; Tatton, W	1
Ahlner, J; Dizdar, N; Kronstrand, R; Larson, G	1
Foley, P; Gerlach, M; Riederer, P	1
Rascol, O	1
Hauser, RA; Hubble, JP; Truong, DD	1
Double, K; Gerlach, M; Reichmann, H; Riederer, P	1
Okamoto, K; Tanaka, M	1
de la Llave, Y; Garcia de Yébenes, J; Garcia-Borreguero, D; Larrosa, O; Schwarz, C	1
Kelsberg, G; Rich, J; Schreck, J; Ward, R	1
Boyce, M; Clarke, A; Corn, TH; Johnson, ES; Johnston, A; MacMahon, DG; Mallard, N; Warrington, S	1
Lachenmayer, L; Riederer, P	1
Endo, T; Hamaue, N; Hirafuji, M; Hiroshige, T; Machida, M; Minami, M; Ogata, A; Parvez, SH; Saito, H; Tashiro, K; Terado, M	1
Bertoni, JM; Hauser, RA; Molho, E; Sethi, KD; Waters, CH	1
Hirata, A; Kaida, K; Kamakura, K; Kanzaki, M; Masaki, T; Mochizuki, H; Motoyoshi, K; Nakamura, R	1
Clarke, CE	1
Castro, A; Dapena, MD; Linazasoro, G; Van Blercom, N	1
Nielsen, KK; Stimpel, H; Werdelin, LM; Winge, K	1
Kang, SY; Lee, MH; Lee, SK; Sohn, YH	1
Jenner, P	1
Koller, WC; Tetrud, JW	1
Riederer, PF; Youdim, MB	1
Clarke, C; Moore, AP	3
Bellik, L; Marco, JI; Romera, M; Sanz, E; Unzeta, M	1
Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Rudolph, A; Tanner, CM	1
Klein, C; Rabey, JM; Stryjer, R; Treves, TA	1
Kurlan, R	1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C	1
Waters, C	1
Gaszner, P; Miklya, I	1
Argyriou, AA; Papapetropoulos, S	1
Chen, JJ; Swope, DM	1
Counsell, CE; Ives, N; Macleod, AD; Stowe, R	1
Shults, CW	2
Bate, G; Kirkpatrick, P; Schapira, A	1
Bhat, V; Weiner, WJ	1
Adler, CH; Thorpy, MJ	1
Lew, MF	1
Burgut, FT; Henchcliffe, C; Schumacher, HC	1
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G	1
Bakhle, YS; Youdim, MB	1
Bae, BI; Cascio, MB; Dawson, TM; Dawson, VL; Hara, MR; Hester, LD; Sawa, A; Snyder, SH; Thomas, B	1
Hägglund, J; Heinonen, E; Kaugesaar, T; Mäki-Ikola, O; Pålhagen, S; Palm, R	1
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I	1
Jain, S; Lo, SE	1
Das, SK; Gangopadhya, PK; Ray, J; Roy, T	1
Brodsky, MA; Koudelka, C; Swarztrauber, K	1
Olanow, CW	9
Chang, YL; Fernandez, HH; Munson, SK; Okun, MS; Shapiro, MA	1
Ikeda, N; Inoue, N; Itoh, S; Kudo, K; Nishida, K	1
Herkes, GK; McKay, D; Meagher, LJ; Needham, M	1
Youdim, MB	3
Haapaniemi, HT; Korpelainen, TJ; Myllylä, VV; Pursiainen, V; Sotaniemi, AK	1
Bertoni, J; Kricorian, G; Leehey, M; Lew, MF; Pahwa, R	1
Annanmaki, T; Murros, K; Muuronen, A	1
Dell'Antone, P; Drago, D; IbnLkayat, M; Zatta, P	1
Chen, JJ; Fernandez, HH	2
Hermanowicz, N	1
Poston, KL; Waters, C	1
Akao, Y; Maruyama, W; Naoi, M; Shamoto-Nagai, M; Yamaoka, Y; Yi, H	1
Chen, JJ; Dashtipour, K; Swope, DM	1
Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Tanner, CM	1
Preskorn, SH	1
Klivényi, P; Vécsei, L	1
Weiner, M	1
Lang, AE	1
Jellinger, K; Riederer, P	1
Colucci d'Amato, C; Cristillo, A; Puccini, A; Vizioli, R	1
Calne, DB; Ebert, MH; Eisler, T; Kopin, IJ; Krebs, H; Lake, CR; Murphy, DL; Nelson, R; Teräväinen, H; Weise, V; Whetzel, N	1
Cohen, G	1
Birkmayer, W; Danielczyk, W; Jellinger, K; Koppel, H; Reynolds, GP; Riederer, P; Seemann, D; Ulm, G	1
Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB	1
Hardie, R; Lees, AJ; Sandler, M; Stern, GM	1
Gallai, M; Tariska, I	1
Birkmayer, W; Riederer, P	1
Bihari, K; Csanda, E; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M	1
Rabey, MJ; Streifler, M	1
Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M	1
Goodgold, A; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R	1
Shreeve, C	1
Birkmayer, W	4
Rinne, UK	7
Hardie, RJ; Lees, AJ; Sandler, M; Stern, GM	1
Csanda, E; Tárczy, M	3
Gerstenbrand, F; Poewe, W; Ransmayr, G	2
Hajba, A; Presthus, J	1
Portin, R; Rinne, UK	1
Sandler, M	2
Knoll, J	14
Ekstedt, J; Johansson, F; Oreland, L	1
Bergmann, KJ; Mendoza, MR; Moros, D; Yahr, MD	1
Quinn, NP	2
Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L	1
Zaleska, B	1
Reiderer, P; Reynolds, GP	1
Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S	1
Jenner, P; Marsden, CD; Parkes, JD; Schachter, M; Testa, B	1
Lavie, P; Wajsbort, J; Youdim, MB	1
Longstreth, WT	1
Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ	1
Elsworth, JD; Lees, AJ; Sandler, M; Stern, GM; Ward, C	1
Birkmayer, W; Riederer, P; Youdim, MB	1
Ghika, J	1
Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW	1
Eadie, MJ	1
Brooks, DJ; Morrish, PK; Sawle, GV	1
Ludin, HP	1
Gerlach, M; Riederer, P; Youdim, MB	2
Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J	1
Burns, RS; Davis, TL; Roznoski, M	2
Garcia-Monco, JC; Gomez Beldarrain, M; Padierna, A	1
Janjua, R; Roos, RA; van Kempen, GM	1
Sweeney, PJ	2
Danysz, W; Quack, G; Rogoz, Z; Skuza, G	1
Herrscher, M; Messer-Kremer, M; Sagez, JF; Schlienger, JL	1
Carter, J; Fahn, S; Gauthier, S; Goetz, CG; Golbe, LI; Jankovic, J; Koller, W; Lang, AE; McDermott, MP; Olanow, CW	1
Hastie, IR; Mukherjee, D	1
Heinonen, EH; Kilkku, OI; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA	1
Brannan, T; Yahr, MD	1
Berry, MD; Juorio, AV; Paterson, IA	1
Chiueh, CC; Mohanakumar, KP; Murphy, DL; Wu, RM	1
Chiueh, CC; Krishna, G; Mohanakumar, KP; Murphy, DL; Obata, T; Sternberger, LM; Wu, RM	1
Bhatia, M; Jain, S; Maheshwari, MC	1
Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schyler, D; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP	1
Haas, RH; Hill, LR; Nakano, K; Nasirian, F; Pay, M; Shults, CW; Ward, DM	1
Holdup, D; Liptrot, J; Phillipson, O	1
Bennett, KM; Castiello, U	1
Beizer, JL	1
Quinn, N	3
Lefebvre, H; Moore, N; Noblet, C; Wolf, LM	1
Kopin, IJ	1
Brady, J; Carter, J; Como, P; Growdon, J; Huber, S; Kanigan, B; Kieburtz, K; Landow, E; McDermott, M; Rudolph, A	1
Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T	1
Yoshida, M	1
Finberg, JP; Youdim, MB	2
Lange, KW; Riederer, P; Youdim, MB	2
Goldstein, B; Schneider, LS; Tariot, PN	1
Tipton, KF	1
Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R	1
Waters, CH	3
Kondo, T; Mizuno, Y; Takubo, H; Yokochi, F	2
Standaert, DG; Stern, MB	1
Chamontin, B; Llau, ME; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Tran, MA	1
Finali, G; Piccinin, GL; Piccirilli, M	1
Ward, CD	1
Bransome, ED; Hendry, LB; Rowland, MJ	1
Calne, DB; Uitti, RJ; Vingerhoets, FJ	1
Dichgans, J; Klockgether, T	1
Ahlskog, JE	3
Iacono, RP; Toyama, SC	1
Oakes, D	2
Bulgaru, D; Büttner, T; Klotz, P; Kuhn, W; Przuntek, H; Steinberg, R; Voss, L	1
Clow, A; Glover, V; Sandler, M	1
Stern, G	3
Rinne, JO	2
Heinonen, EH; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA	3
Riederer, P; Youdim, MB	2
Allain, H; Neukirch, HC; Pollak, P	1
Fénelon, G	1
Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B	1
McFarland, HR	1
Boulton, AA; Juorio, AV; Li, XM; Paterson, IA	1
Singer, TP; Tipton, KF	1
Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schlyer, DJ; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP	1
Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW	1
Achiron, A; Djaldetti, R; Dressler, R; Melamed, E; Ziv, I	1
Hubble, JP; Koller, WC; Waters, C	1
Davis, PH; Zweig, RM	1
Koivikko, L; Portin, R; Revonsuo, A; Rinne, JO; Rinne, UK	1
Drummond, SS; Krueger, KM; Metzer, WS; Shea, BR	1
Kofman, OS	2
Lieberman, A	5
Silverstein, PM	1
Cummings, JL	1
Blitzer, A; Bressman, SB; Brin, MF; Fahn, S; Hunt, A; Stewart, C; Winfield, L	1
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Calne, DB	2
Lees, AJ	3
Szirmai, I; Tárczy, M	1
Arányi, P; Gaál, J; Kardos, V; Király, I; Kollár, E; Patthy, M; Sziráki, I; Tömösközi, Z	1
Heinonen, E; Kilkku, O; Mäki-Ikola, O	1
Anderson, KE; Girdwood, AC; Wilson, JA	1
Godbold, JH; Koller, W; Olanow, CW	1
Jenner, P; Silva, MT; Watts, PM	1
Bland, R; MacMahon, DG	1
Boulton, AA; Lai, CT; Yu, PH	1
Gerlach, M; Riederer, P; Vogt, H	1
Jellinger, KA	1
Checkoway, H; Franklin, GM; Kushleika, J; Moon, JD; Smith-Weller, T; Swanson, PD; Woods, JS	1
Ebadi, M; Hao, R; Pfeiffer, RF	1
Fahn, S	1
Ahlskog, JE; Low, PA; Nickander, KK; O'Brien, JF; Tyce, GM; Uitti, RJ	1
Brownlee, HJ; Stacy, M	1
Calzetti, S; Cassio, A; Negrotti, A	1
Iacano, RP; Mohamed, AS; Schoonenberg, T	1
Newton, W	1
Bergus, G	1
Hayes, HD	1
Dalrymple-Alford, JC; Donaldson, IM; Jamieson, CF	1
Kishore, A; Snow, BJ	1
Falip, R; López-Arlandis, J; Manzanares, R; Martín, R; Matías-Guiu, J; Provencio, R; Ruiz, C	1
Bowes, SG; Charlett, A; Dickins, J; Dobbs, RJ; Dobbs, SM; Faulkner, G; Hunt, WB; Kirollos, C; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C	1
Kovacs, AB; Mally, J; Stone, TW	1
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D	1
Dierks, T; Grosse, H; Kuhn, W; Müller, T; Rommelspacher, H	1
Dubois, B; Montastruc, JL	1
Bloem, BR; Klaassen, AA; van Hilten, JJ	1
Fazzini, E; Fowler, JS; Volkow, ND	1
Korczyn, AD; Nisipeanu, P	1
Fedorova, NV; Glozman, ZhM; Saltykova, NM	1
Mahmood, I; Marinac, JS; Mason, WD; Willsie, S	1
Dostert, P; La Croix, R; Strolin Benedetti, M	1
Schneider, E	1
Hely, MA; Morris, JG	1
Charlett, A; Dobbs, RJ; Dobbs, SM	1
Montastruc, JL; Rascol, O; Senard, JM	1
Temlett, JA	1
Koller, WC	3
Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Rinne, UK; Sotaniemi, K	1
Desser, H; Gerlach, M; Riederer, P; Youdim, MB	1
Lengyel, J; Magyar, K; Szende, B; Tekes, K	1
Chalmers-Redman, RM; Ju, WY; Tatton, NA; Tatton, WG; Wadia, JS	1
Shan, DE; Yeh, SI	1
Fahn, S; Godbold, J; Langston, JW; Olanow, CW	1
Heinonen, E; Mäki-Ikola, O	1
Araya, F; Castillo, JL; Miranda, CM; Sáez, D	1
Head, J; Lees, AJ; Shlomo, YB	1
Ajax, T; Dobson, J; Rodnitzky, R	1
Myllylä, VV; Sotaniemi, K; Suominen, K; Tolonen, U; Turkka, J	1
Boas, J; Larsen, JP	1
Cui, L; LeWitt, P; Oakes, D	1
Arenas, J; Benito-León, J; Campos, Y; Gasalla, T; Jiménez-Jiménez, FJ; Martín, MA; Molina, JA; Ortí-Pareja, M; Rubio, JC	1
Armstrong, RA; Blair, JA; Hodgkins, PS; Winsper, SJ	1
Factor, S; Hubble, J; Kurlan, R; Richard, IH; Suchowersky, O; Tanner, C; Waters, C	1
Sethi, KD	1
Hakulinen, P; Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Sotaniemi, KA	1
Andreu, N; Damase-Michel, C; Montastruc, JL; Rascol, O; Senard, JM	1
Alexander, B; Ritter, JL	1
Kondo, T; Mizuno, Y	1
Schulzer, M	1
Riggs, JE	2
Dostert, P; Hashizume, Y; Kasamatsu, T; Kohda, K; Maruyama, W; Naoi, M; Takahashi, T	1
Stern, MB	1
Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P	1
Hantler, CB; Noorily, SH; Sako, EY	1
Jenner, P; Schapira, AH; Silva, MT	1
Jiménez-Jiménez, FJ; Molina, JA	1
Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ	1
Ballering, LA; Steur, EN	1
Tolosa, E; Valldeoriola, F	1
Hauser, RA; Zesiewicz, TA	2
McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF	1
Oertel, WH; Quinn, NP	1
Hagell, P; Odin, P; Vinge, E	1
Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F	1
Kupsch, A; Oertel, WH	1
Furst, P; Kragten, E; Lalande, I; Muller, D; Roggo, S; Schindler, P; van Oostrum, J; Waldmeier, P; Zimmermann, K	1
Maloteaux, JM	1
Imke, S	1
Charlett, A; Dobbs, RJ; Dobbs, SM; Peterson, DW; Purkiss, AG; Weller, C; Wright, DJ	1
Ciccone, CD	1
Breteler, MM	1
Abrams, KR	1
Arenas, J; Benito-León, J; Cisneros, E; de Bustos, F; Gasalla, T; Jiménez-Jiménez, FJ; Molina, JA; Navarro, JA; Ortí-Pareja, M; Tallón-Barranco, A	1
Chouinard, S; Fahn, S	1
Giladi, N; Hocherman, S; Levin, G; Youdim, MB	1
Lengyel, J; Magyar, K; Szatmáry, I; Szende, B; Tarczali, J	1
De Weerdt, W; Dom, R; Lesaffre, E; Nieuwboer, A	1
Ben-Shlomo, Y; Churchyard, A; Head, J; Hurwitz, B; Lees, AJ; Ockelford, J; Overstall, P	1
Mytilineou, C; Olanow, CW; Tatton, W	1
Brannan, T; Martínez-Tica, J; Prikhojan, A; Yahr, MD	1
Ruggieri, S; Silver, DE	1
Fahn, S; Kuskowski, MA; Vatassery, GT	1
Heinonen, EH; Myllylä, V	1
Armstrong, B; Hollowell, J; Nichols, T; Thorogood, M	1
Dorflinger, EE; Hauser, RA; Molho, E; Pedder, S; Shale, H	1
Coyle, J; Hobson, P; Meara, J	1
Heinonen, E; Myllylä, V	1
Hägglund, J; Heinonen, EH; Kaugesaar, T; Kontants, H; Mäki-Ikola, O; Pålhagen, S; Palm, R; Turunen, J	1
Aguilar, MV; de Bustos, F; González-Muñoz, MJ; Jiménez-Jiménez, FJ; Martínez-Para, MC; Martínez-Salio, A; Mateos-Vega, CJ; Meseguer, I; Molina, JA; Ortí-Pareja, M; Zurdo, M	1
Heinonen, EH; Kilkku, O; Lammintausta, R; Larsen, JP; Mäki-Ikola, O; Myllylä, VV; Olanow, CW; Pålhagen, S; Przuntek, H; Rinne, UK; Sotaniemi, KA	1
Shoulson, I	5
Counsell, C	1
Retz, W; Riederer, P; Rösler, M; Thome, J	1
Mahmood, I	1
Aaltonen, H; Heinonen, E; Kilkku, O; Mäki-Ikola, O	1
Meco, G; Raschetti, R; Spila-Alegiani, S; Vanacore, N	1
Conrad, B; Dichgans, J; Kraus, PH; Krauseneck, P; Pergande, G; Przuntek, H; Rinne, U; Schimrigk, K; Schnitker, J; Vogel, HP	1
Churchyard, A; Lees, AJ; Mathias, CJ	1
Kurlan, R; Siderowf, A	1
Hubble, JP	1
Bryson, HM; Chrisp, P; Milne, RJ	1
Chari, G; Gold, M; Hauser, RA; Zesiewicz, TA	1
Castronuovo, J; Feigin, A; Innis, RB; Marek, KL; Seibyl, JP; Sheff, K; Zoghbi, S	1
Ballering, LA; Jansen Steur, EN	1
Ballesteros, J; Jaúregui, JV; Meana, JJ; Ruiz, J; Soto, J; Ulibarri, I	1
Boas, J; Erdal, JE; Larsen, JP	1
Barcenilla, B; Berbel, A; de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Molina, JA; Villanueva, C; Zurdo, M	1
Cole, WC; Kumar, B; Prasad, KN	1
Stacy, M	1
Bémeur, C; Lambert, J; Montgomery, J; Ste-Marie, L; Vachon, L	1
Ghaemi, M; Rudolf, J; Schmülling, S	1
Haberle, D; Magyar, K	1
Maruyama, W; Naoi, M	2
Ahuja, GK; Behari, M; Dixit, SN	1
Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P	1
Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW	1
Myllylä, V	1
Damier, P	1
Mauro, VF; Ohlinger, MJ; Rose, LM	1
Maruyama, W; Naoi, M; Yagi, K; Youdim, M	1
Klegeris, A; McGeer, PL	1
Hillier, CE; Hinds, NP; Wiles, CM	1
Akao, Y; Maruyama, W; Nakagawa, Y; Naoi, M; Takahashi, T	1
Langston, JW; Tanner, CM	1
Davey, PG; Donnan, PT; MacDonald, TM; Steinke, DT; Stubbings, C	1
Haapaniemi, TH; Kallio, MA; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U	1
Bradford, HF; Goggi, J; Jauniaux, E; Riaz, SS; Stern, GM; Theofilopoulos, S	1
Sternon, J; Supiot, F; Zegers de Beyl, D	1
Marsh, C; Preskorn, SH; Shad, MU	1
Boulton, AA; Cools, AR; Kato, AC; Tatton, WG; Waldmeier, PC	1
Arenas, J; Barcenilla, B; Berbel, A; Camacho, A; De Bustos, F; Gómez, P; Gómez-Escalonilla, C; Jiménez-Jiménez, FJ; Molina, JA; Vargas, C; Zurdo, M	1
Bocsi, J; Bökönyi, G; Kéri, G; Magyar, K; Szende, B; Timár, F	1
Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA	1
Awaya, T; Chiba, K; Hayase, N; Kimura, K; Matsubara, K; Ogawa, S; Senda, T; Shimizu, K; Uezono, T	1
Bizzarri, G; Calzetti, S; Negrotti, A	1
Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U	1
Fahn, S; Giladi, N; Jankovic, J; McDermott, MP; Przedborski, S; Stern, M; Tanner, C	1
Ball, J	1
Ahlskog, JE; Van Gerpen, JA	1
Ben-Shlomo, Y; Lees, A	1
Amano, T; Fukuuchi, Y; Ito, D; Sato, H	1
Miyoshi, K	1
Hidestrand, M; Ingelman-Sundberg, M; Nyman, L; Oscarson, M; Pelkonen, O; Salonen, JS; Turpeinen, M	1
Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ	1
Horiuchi, E; Kanazawa, I; Murata, M	1
Jankovic, J	1
Ebadi, M; El Refaey, H; Sharma, S; Shavali, S	1
Goetz, CG; Leurgans, S; Raman, R	1
Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N	1
Lander, CM; Lees, A; Stern, G	1
Antal, J; Antóny, M; Csanaky, A; Csanda, E	1
Reynolds, GP; Riederer, P; Sandler, M	1
Birkmayer, W; Jellinger, K; Riederer, P; Youdim, MB	1
Yahr, MD	2
Ashford, A; Glover, V; Sandler, M; Stern, GM	1
Lees, AJ; Sandler, M; Stern, GM	1
Rinne, UK; Siirtola, T; Sonninen, V	1
Jellinger, K; Reynolds, GP; Riederer, P; Sandler, M; Seemann, D	1
Berg, MJ; Collier, DS; Fincham, RW	1
Siemers, E	1
Nag, D	1
Castoldi, AF; Checkoway, H; Costa, LG; Lund, BO; Swanson, PD; Woods, JS	1
Follender, AB; Hughes, PL; Jermain, DM	1
Dimitsopulos, T; Kurlan, R	1
Ahuja, GK; Behari, M; Prasad, K; Singh, K	1
Dietrichs, E	1
Calne, DB; Mak, E; Schulzer, M	1
Levivier, M; Przedborski, S	1
Ecseryné Puskás, M; Hermecz, I	1
Kovács, A	1
Martin, WR	1
Horstink, MW; Kuiper, MA; Wolters, EC	1
Baronti, F; Boldry, RC; Chase, TN; Davis, TL; Mouradian, MM	1
Málly, J	1
Grimes, D; Mohr, E; Vezina, P	1
Langston, JW; Tetrud, JW	3
Calne, D; Olanow, CW	1
Madeja, UD	1
Szelenyi, I; Wessel, K	1
Anderson, JJ; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R; Gillespie, M	1
Bodkin, JA; Cohen, BM; Zornberg, GL	1
Clough, CG	1
Heinonen, EH; Lammintausta, R	1
Marsden, CD	1
Kuhn, W; Przuntek, H	2
Robin, DW	1
Horowski, R; Runge, I	1
Hietanen, MH	1
Chrisp, P; Mammen, GJ; Sorkin, EM	1
Heinonen, EH; Ingvarsson, PE; Johnels, B; Matousek, M; Steg, G	1
Oreland, L	1
Fazzini, E; Lieberman, A	1
Allain, H; Cougnard, J; Neukirch, HC	1
Chacón, JN; Truscott, TG	1
Elizan, TS; Moros, DA; Yahr, MD	1
Fuller, MA; Tolbert, SR	1
Grimes, JD	1
Paljärvi, L; Rinne, JO; Rinne, UK; Röyttä, M; Rummukainen, J	1
Jacobs, MB; Varon, J	1
Cedarbaum, JM; Green-Parsons, A; Toy, LH	1
Bruggi, P; Horowski, R; Martignoni, E; Nappi, G; Pacchetti, C; Rainer, E; Runge, I	1
Asari, S; Goldstein, M; Nakashima, H; Nishimoto, A	1
Hauser, RA; Olanow, CW	1
Ogawa, N	1
Boyson, SJ	1
Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H	1
Nagatsu, T; Naoi, M	1
Alimov, IIu; Ganiev, KhG; Nazhmidinova, MN	1
Ahlskog, JE; Wilkinson, JM	1
Bhatti, AR; Devlin, AJ; Ramsden, DB; Williams, AC	1
Raub, W	1
Calesnick, B	1
George, CF; Robertson, DR	1
Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M	1
Baas, H; Fischer, PA	2
Kalász, H; Kerecsen, L; Knoll, J; Pucsok, J	1
Golbe, LI; Langston, JW; Shoulson, I	1
Cotton, P	1
Allen, WA	1
deVries, J; Suchowersky, O	1
Giron, LT; Koller, WC	1
Langston, JW	2
Bodian, CA; Elizan, TS; Mendoza, MR; Moros, DA; Pang, S; Yahr, MD	3
Fornadi, F; Ulm, G	2
Curry, SH; Eatough, VM; Frankel, JP; Kempster, PA; Lees, AJ; Rogers, D; Stern, GM	1
Poungvarin, N; Viriyavejakul, A	1
Kurth, MC; Langston, JW; Tetrud, JW	1
Pearce, JM	1
Susel, Z; Yarnitsky, D	1
Heikkila, RE; Sieber, BA; Terleckyj, I	1
Hodges, LC; Rapp, CG	1
Kraus, P; Kuhn, W; Przuntek, H	1
Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W	1
Lewin, R	3
Golbe, LI	2
Chung, E; Dvorozniak, MT; Lee, DH; Mendoza, M; van Woert, MH; Yahr, MD	1
Nightingale, SL	1
D'Anglejan-Chatillon, J	1
Friedman, JH	1
Eatough, VM; Frankel, JP; Kempster, PA; Lees, AJ; Nathanson, M; Stern, GM; Stibe, CM	1
Heinonen, EH; Rinne, UK	1
Heinonen, EH; Rinne, UK; Tuominen, J	1
Parker, S; Teychenne, PF	1
Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A	1
Eatough, V; Frankel, J; Lees, AJ; Stern, GM	1
Boesen, F; Dupont, E; Heinonen, E; Mikkelsen, B; Mogensen, P; Rasmussen, C; Sivertsen, B	1
Elizan, TS; Moros, D; Yahr, MD	1
Heinonen, EH; Myllylä, VV; Sotaniemi, KA; Tuominen, J	1
Anttila, M; Heinonen, EH; Kotila, M; Lamintausta, R; Myllylä, V; Rinne, UK; Salonen, JS; Savijärvi, M; Sotaniemi, K	1
Goetz, CG; Klawans, HL; Rajput, AH; Tanner, CM; Thiessen, B; Uitti, RJ	1
Birkmayer, G; Danielczyk, W; Kienzl, E; Konradi, C; Riederer, P; Schay, V; Sofic, E; Youdim, MB	1
Agnoli, A; Carta, A; Denaro, A; Meco, G; Ruggieri, S; Stocchi, F	1
Jenner, P; Marsden, CD	1
Gibb, C; Glover, V; Sandler, M	1
Cacudi, N; de Mari, M; Ferrari, E; Iliceto, G; Lamberti, P	1
Caraceni, T; Giovannini, P; Piccolo, I; Scigliano, G	1
Birkmayer, GD; Birkmayer, W	1
Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F	1
Csanda, E; Takáts, A; Tárczy, M	1
Caraceni, T; Giovannini, P; Grassi, MP; Martignoni, E; Nappi, G; Pacchetti, C; Piccolo, I	1
Birkmayer, JD; Birkmayer, W	1
Dostert, P; Strolin Benedetti, M	1
Aminoff, MJ	1
Merz, B	1
Karaban', IN; Man'kovskiĭ, NB; Mialovitskaia, EA	1
Berstad, J; Lien, K; Presthus, J	1
Dubuis, R	1
Duvoisin, RC; Golbe, LI	1
Gibb, C; Glover, V; Sandler, M; Willoughby, J	1
Foo, SH; Gopinathan, G; Lieberman, AN; Neophytides, A	1
Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN	1
Grimes, JD; Hassan, MN; Thakar, JH	1
Leenders, KL	1
Demonet, JF; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Simonetta, M	1
Sheng, JG; Xu, DL; Yu, HZ	1
Calne, DB; Rinne, UK	1
Golbe, LI; Sonsalla, PK	1
Golbe, LI; Menza, MA	1
Kadykov, AS; Shakhparonova, NV; Shvedkov, VV; Stoliarova, LG	1
Brodersen, P; Gulliksen, G; Philbert, A; Stigård, A	1
Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P	1
Adam, AM	1
Daniele, D; Gillio, S; Scarzella, L; Trebini, F	1
Wirz, D	1

Reviews

220 review(s) available for selegiline and Idiopathic Parkinson Disease

Article	Year
Multi-target-directed ligands to combat neurodegenerative diseases. Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid	2008
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements. Current neuropharmacology, 2022, Volume: 20, Issue:7 Topics: Antiparkinson Agents; Dietary Supplements; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2022
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. Journal of Parkinson's disease, 2022, Volume: 12, Issue:2 Topics: Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2022
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:5-6 Topics: Antiparkinson Agents; Dopamine Agents; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2022
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action. Current neuropharmacology, 2023, Volume: 21, Issue:5 Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline	2023
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled European journal of neurology, 2023, Volume: 30, Issue:4 Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide	2023
Selegiline: a molecule with innovative potential. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:5 Topics: Animals; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2020
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:2 Topics: alpha-Synuclein; Animals; Apoptosis; Homeostasis; Humans; Indans; Mitochondria; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2020
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:9 Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation	2020
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. European journal of clinical pharmacology, 2020, Volume: 76, Issue:12 Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2020
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis. Scientific reports, 2017, 04-04, Volume: 8 Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes	2017
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:11 Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotection; Neuroprotective Agents; Parkinson Disease; Selegiline	2018
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:11 Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Selegiline	2018
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. British journal of clinical pharmacology, 2018, Volume: 84, Issue:9 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2018
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Current neuropharmacology, 2019, Volume: 17, Issue:9 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2019
Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis. Aging clinical and experimental research, 2020, Volume: 32, Issue:5 Topics: Activities of Daily Living; Combined Modality Therapy; Drug Therapy, Combination; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Selegiline; Treatment Outcome	2020
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7 Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline	2013
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert review of neurotherapeutics, 2013, Volume: 13, Issue:6 Topics: Animals; Apoptosis; Gene Expression; Genes, bcl-2; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Selegiline	2013
[The role of alpha-synuclein in Parkinson's disease]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2014, Volume: 16, Issue:2 Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Endocytosis; Exocytosis; Humans; Lewy Bodies; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Prions; Protein Structure, Secondary; Selegiline	2014
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:13 Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2014
Pooled analysis of phase III with entacapone in Parkinson's disease. Acta neurologica Scandinavica, 2014, Volume: 130, Issue:4 Topics: Aged; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline	2014
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:10 Topics: Animals; Antiparkinson Agents; Catechols; Disease Progression; Humans; Indans; Monoamine Oxidase Inhibitors; Nitriles; Oxidative Stress; Parkinson Disease; Selegiline	2014
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Molecular psychiatry, 2016, Volume: 21, Issue:11 Topics: Aging; Alzheimer Disease; Animals; Brain; Catecholamines; Depressive Disorder, Major; Dopamine; History, 20th Century; Humans; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Rats; Selegiline	2016
[Motor symptoms in Parkinson disease]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Sep-25, Volume: 128, Issue:18 Topics: Age Factors; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Dystonia; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Selegiline; Treatment Outcome; Tremor	2008
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings]. Ideggyogyaszati szemle, 2009, Jan-30, Volume: 62, Issue:1-2 Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone	2009
'Bad guys' among the antiparkinsonian drugs. Psychiatria Danubina, 2009, Volume: 21, Issue:1 Topics: Antiparkinson Agents; Benzophenones; Cholinergic Antagonists; Cognition; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Survival Rate; Tolcapone; Treatment Outcome	2009
MAO-B inhibitor know-how: back to the pharm. Neurology, 2009, Apr-14, Volume: 72, Issue:15 Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2009
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	2009
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. Fortschritte der Neurologie-Psychiatrie, 2010, Volume: 78 Suppl 1 Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline	2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Progress in neurobiology, 2010, Volume: 92, Issue:3 Topics: Animals; Antiparkinson Agents; Cells, Cultured; Disease Models, Animal; Humans; Indans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Protein Structure, Quaternary; Selegiline	2010
[The feasibility of synthetic enhancer substances for preventive nanotherapy]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:3 Topics: Alzheimer Disease; Animals; Brain Stem; Catecholamines; Depressive Disorder; Feasibility Studies; Humans; Liposomes; Nanomedicine; Neurons; Nootropic Agents; Parkinson Disease; Preventive Medicine; Selegiline; Serotonin; Ubiquitin-Protein Ligases	2010
Selegiline and rasagiline: twins or distant cousins? The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2011, Volume: 26, Issue:1 Topics: Humans; Inactivation, Metabolic; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2011
The pharmacology of selegiline. International review of neurobiology, 2011, Volume: 100 Topics: Animals; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline; Structure-Activity Relationship	2011
Neurological effects of psychopharmacological agents. Seminars in clinical neuropsychiatry, 2002, Volume: 7, Issue:3 Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; Bundle-Branch Block; Delirium; Depressive Disorder; Humans; Lithium; Male; Nervous System Diseases; Parkinson Disease; Psychotropic Drugs; Selegiline	2002
MAO-B inhibitors for the treatment of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4 Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	2002
[Monoamine oxidase inhibitors: prospects for the use in clinical practice]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:8 Topics: Alzheimer Disease; Animals; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Selegiline; Tourette Syndrome	2002
Practical importance of neuroprotection in Parkinson's disease. Journal of neurology, 2002, Volume: 249 Suppl 3 Topics: Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Selegiline	2002
Recent advances in Parkinson's disease. Ideggyogyaszati szemle, 2002, Nov-20, Volume: 55, Issue:11-12 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	2002
[Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2003, Volume: 121, Issue:3 Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Parkinson Disease; Selegiline; Synaptic Transmission; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2003
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:5 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Glyceraldehyde-3-Phosphate Dehydrogenases; HSP70 Heat-Shock Proteins; Humans; Monoamine Oxidase; Neurons; Neuroprotective Agents; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Selegiline; Superoxide Dismutase	2003
The relevance of preclinical studies for the treatment of Parkinson's disease. Journal of neurology, 2003, Volume: 250 Suppl 1 Topics: Antiparkinson Agents; Benzophenones; Drug Evaluation, Preclinical; Humans; Levodopa; Neuroprotective Agents; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone	2003
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. Journal of neural transmission. Supplementum, 2003, Issue:65 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Selegiline	2003
Clinical inquiries. What is the best initial treatment of Parkinson's disease? The Journal of family practice, 2003, Volume: 52, Issue:11 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	2003
Selegiline's neuroprotective capacity revisited. Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:11 Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Parkinson Disease; Recovery of Function; Selegiline	2003
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5 Topics: Antiparkinson Agents; Brain; Cost-Benefit Analysis; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Selegiline; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2004
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2 Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline	2004
A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2 Topics: Absorption; Administration, Oral; Antiparkinson Agents; Biotransformation; Forecasting; Freeze Drying; Humans; Monoamine Oxidase Inhibitors; Mouth Mucosa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Solubility; Tablets; Treatment Outcome	2004
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2 Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Cheese; Child; Child, Preschool; Dopamine; Drug Design; Humans; Hypertension; Infant; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neurotransmitter Agents; Parkinson Disease; Selegiline; Tyramine	2004
Clinical trials of neuroprotection for Parkinson's disease. Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2 Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone	2004
Parkinson's disease. Clinical evidence, 2003, Issue:10 Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	2003
Parkinson's disease. Clinical evidence, 2004, Issue:11 Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus	2004
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone	2005
Other pharmacological treatments for motor complications and dyskinesias. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11 Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline	2005
Treatment possibilities of Alzheimer's disease. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2004, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Antiparkinson Agents; Benzofurans; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Genetic Predisposition to Disease; Humans; Mesencephalon; Neuroprotective Agents; Parkinson Disease; Reproducibility of Results; Research Design; Selegiline; United States	2004
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Journal of clinical pharmacology, 2005, Volume: 45, Issue:8 Topics: Animals; Clinical Trials as Topic; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2005
Monoamine oxidase B inhibitors for early Parkinson's disease. The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline	2005
Parkinson's disease. Clinical evidence, 2005, Issue:13 Topics: Deep Brain Stimulation; Deglutition Disorders; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus	2005
Parkinson's disease. Diagnosis and the initiation of therapy. Minerva medica, 2005, Volume: 96, Issue:3 Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor	2005
Parkinson's disease and sleep. Neurologic clinics, 2005, Volume: 23, Issue:4 Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Fatigue; Humans; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Risk Factors; Selegiline; Sleep Disorders, Circadian Rhythm	2005
Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:6 Topics: Administration, Oral; Dose-Response Relationship, Drug; Expert Testimony; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Parkinson Disease; Pharmaceutical Preparations; Selegiline	2005
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:6 Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2005
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British journal of pharmacology, 2006, Volume: 147 Suppl 1 Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2006
Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease. Neurology, 2006, Apr-25, Volume: 66, Issue:8 Topics: Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	2006
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Current Alzheimer research, 2006, Volume: 3, Issue:5 Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Humans; Hydroxyquinolines; Indans; Models, Biological; Neuroprotective Agents; Parkinson Disease; Selegiline	2006
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs & aging, 2007, Volume: 24, Issue:8 Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline	2007
Zydis selegiline in the management of Parkinson's disease. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:15 Topics: Animals; Antiparkinson Agents; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Technology, Pharmaceutical	2007
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clinical therapeutics, 2007, Volume: 29, Issue:9 Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2007
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 2007, Volume: 27, Issue:12 Pt 2 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2007
Update on antiparkinsonian agents. Geriatrics, 1982, Volume: 37, Issue:9 Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance	1982
[Biochemical bases of Parkinson disease]. Recenti progressi in medicina, 1984, Volume: 75, Issue:10 Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Selegiline; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase	1984
Anti-parkinsonian drugs today. Drugs, 1984, Volume: 28, Issue:3 Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline	1984
The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia, 1984, Nov-15, Volume: 40, Issue:11 Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine	1984
[Progress in the treatment of degenerative diseases of the nervous system. Selected problems]. Neurologia i neurochirurgia polska, 1980, Volume: 14, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Humans; Huntington Disease; Lithium; Neostigmine; Parkinson Disease; Penicillamine; Phthalazines; Selegiline; Tetrabenazine; Tiapamil Hydrochloride	1980
[Stage-adjusted treatment of idiopathic Parkinson syndrome]. Wiener medizinische Wochenschrift (1946), 1995, Volume: 145, Issue:13 Topics: Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Cholinergic Antagonists; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline	1995
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochemical pharmacology, 1995, Jun-29, Volume: 50, Issue:1 Topics: Animals; Humans; Nervous System Diseases; Parkinson Disease; Selegiline; Vitamin E	1995
Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1995, Volume: 49, Issue:4 Topics: Aging; Alzheimer Disease; Animals; Antiparkinson Agents; Drug Administration Schedule; Humans; Parkinson Disease; Selegiline; Substantia Nigra	1995
Parkinson's disease: managing symptoms and preserving function. Geriatrics, 1995, Volume: 50, Issue:9 Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combinations; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Selegiline	1995
[Changing drug therapy of Parkinson disease]. Duodecim; laaketieteellinen aikakauskirja, 1993, Volume: 109, Issue:20 Topics: Antiparkinson Agents; Corpus Striatum; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Synaptic Transmission	1993
Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Progress in neurobiology, 1994, Volume: 44, Issue:2 Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Depressive Disorder; Humans; Longevity; Mental Disorders; Monoamine Oxidase Inhibitors; Nervous System Diseases; Parkinson Disease; Schizophrenia; Selegiline	1994
Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Annals of the New York Academy of Sciences, 1994, Nov-17, Volume: 738 Topics: 1-Methyl-4-phenylpyridinium; Alzheimer Disease; Animals; Antioxidants; Corpus Striatum; Free Radicals; Humans; Hydroxyl Radical; Lipid Peroxidation; Monoamine Oxidase; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra	1994
In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Annals of the New York Academy of Sciences, 1994, Nov-17, Volume: 738 Topics: Animals; Antioxidants; Basal Ganglia; Corpus Striatum; Dopamine; Free Radical Scavengers; Free Radicals; Humans; Hydroxyl Radical; Melanins; MPTP Poisoning; Nerve Degeneration; Parkinson Disease; Rats; Salicylates; Selegiline; Substantia Nigra	1994
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. Journal of neural transmission. Supplementum, 1994, Volume: 43 Topics: Clinical Trials as Topic; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Time Factors; Vitamin E	1994
Treatment options in Parkinson's disease. American pharmacy, 1995, Volume: NS35, Issue:1 Topics: Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline	1995
Drug treatment of Parkinson's disease. BMJ (Clinical research ed.), 1995, Mar-04, Volume: 310, Issue:6979 Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1995
Is selegiline neuroprotective in Parkinson's disease? Journal of neural transmission. Supplementum, 1994, Volume: 41 Topics: Animals; Brain; Clinical Trials as Topic; Enzyme Induction; Glutamic Acid; Humans; Hydrogen Peroxide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotoxins; Parkinson Disease; Selegiline; Superoxide Dismutase	1994
Monoamine oxidase and catecholamine metabolism. Journal of neural transmission. Supplementum, 1994, Volume: 41 Topics: Animals; Catechol O-Methyltransferase; Catecholamines; Humans; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1994
[Parkinson's disease--current topics]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1994, Mar-10, Volume: 83, Issue:3 Topics: Adult; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1994
Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: Animals; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1994
Biochemical actions of l-deprenyl (selegiline). Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: Animals; Autonomic Nervous System; Enzyme Induction; Humans; Oxidation-Reduction; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Selegiline; Superoxide Dismutase	1994
Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: Alzheimer Disease; Depressive Disorder; Drug Synergism; Humans; Parkinson Disease; Selegiline; Substance-Related Disorders	1994
What is it that l-deprenyl (selegiline) might do? Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Monoamine Oxidase Inhibitors; Nervous System; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1994
Update on the management of Parkinson's disease. The Medical clinics of North America, 1993, Volume: 77, Issue:1 Topics: Depression; Diagnosis, Differential; Dopamine Agents; Hallucinations; Humans; Levodopa; Parkinson Disease; Selegiline	1993
Strategies in the treatment of early Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1993, Volume: 146 Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline	1993
Treatment of Parkinson's disease. From theory to practice. Postgraduate medicine, 1994, Volume: 95, Issue:5 Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline	1994
Effects of dopaminergic drugs on superoxide dismutase: implications for senescence. Journal of neural transmission. Supplementum, 1993, Volume: 40 Topics: Aging; Animals; Corpus Striatum; Enzyme Induction; Free Radicals; Humans; Isatin; Life Expectancy; Nerve Degeneration; Parkinson Disease; Pergolide; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase	1993
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. Journal of neural transmission. Supplementum, 1993, Volume: 40 Topics: Aging; Alzheimer Disease; Animals; Avoidance Learning; Catalase; Corpus Striatum; Drug Therapy, Combination; Learning; Levodopa; Male; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase	1993
Die Pathoklise [Parkinson's disease]. Journal of neural transmission. Supplementum, 1993, Volume: 40 Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra	1993
A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: Free Radicals; Humans; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Nerve Degeneration; Parkinson Disease; Reactive Oxygen Species; Selegiline; Substantia Nigra	1993
Nigral degeneration in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Substantia Nigra	1993
The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: Corpus Striatum; Dopamine; Humans; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroglia; Parkinson Disease; Polyamines; Reactive Oxygen Species; Selegiline; Substantia Nigra	1993
Neuroprotection by anti-oxidant strategies in Parkinson's disease. European neurology, 1993, Volume: 33 Suppl 1 Topics: Antioxidants; Corpus Striatum; Dopamine; Humans; Monoamine Oxidase; Parkinson Disease; Reactive Oxygen Species; Receptors, Dopamine; Selegiline; Substantia Nigra; Vitamin E	1993
Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of neurochemistry, 1993, Volume: 61, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aging; Animals; Biological Transport; Humans; Mitochondria; Nervous System; Oxidation-Reduction; Parkinson Disease; Selegiline; Species Specificity	1993
MAO-B inhibitors in Parkinson's disease. Advances in neurology, 1993, Volume: 60 Topics: Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Receptors, Dopamine; Selegiline	1993
Treatment of Parkinson's disease. Current opinion in neurology and neurosurgery, 1993, Volume: 6, Issue:3 Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline	1993
A scientific rationale for protective therapy in Parkinson's disease. Journal of neural transmission. General section, 1993, Volume: 91, Issue:2-3 Topics: Antiparkinson Agents; Calcium; Cell Death; Clinical Trials as Topic; Dopamine; Free Radicals; Homeostasis; Humans; Mitochondria; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Selegiline	1993
Moderate Parkinson's disease. Strategies for maximizing treatment. Postgraduate medicine, 1996, Volume: 99, Issue:1 Topics: Antiparkinson Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	1996
Lewy body diseases with dementia: pathophysiology and treatment. Brain and cognition, 1995, Volume: 28, Issue:3 Topics: Alzheimer Disease; Cerebral Cortex; Corpus Striatum; Humans; Lewy Bodies; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Substantia Nigra	1995
Controversies in the therapy of Parkinson's disease. Advances in neurology, 1996, Volume: 69 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Treatment options for early Parkinson's disease. American family physician, 1996, Volume: 53, Issue:4 Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	1996
Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clinic proceedings, 1996, Volume: 71, Issue:7 Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline	1996
Drug management of Parkinson's disease. Canadian family physician Medecin de famille canadien, 1996, Volume: 42 Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl	1996
Controversies in the treatment of Parkinson's disease. Current opinion in neurology, 1996, Volume: 9, Issue:4 Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	1996
New directions in the drug treatment of Parkinson's disease. Drugs & aging, 1996, Volume: 9, Issue:3 Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	1996
(-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1996, Volume: 50, Issue:6-7 Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Selegiline monotherapy in the treatment of Parkinson's disease. Neurology, 1996, Volume: 47, Issue:6 Suppl 3 Topics: Antiparkinson Agents; Humans; Parkinson Disease; Selegiline	1996
Role of selegiline in combination therapy of Parkinson's disease. Neurology, 1996, Volume: 47, Issue:6 Suppl 3 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology, 1996, Volume: 47, Issue:6 Suppl 3 Topics: Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Survival Analysis	1996
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Binding Sites; Clinical Trials as Topic; Corpus Striatum; Disease Progression; gamma-Aminobutyric Acid; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Nootropic Agents; Oxidative Stress; Parkinson Disease; Polyamines; Receptors, N-Methyl-D-Aspartate; Selegiline; Substantia Nigra	1996
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Age Factors; Animals; Apoptosis; Dopamine; Humans; Hypertension; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Norepinephrine; Parkinson Disease; PC12 Cells; Rats; Selegiline	1996
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Expression Regulation; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neurites; Neuroglia; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Protein Synthesis Inhibitors; Rats; Selegiline	1996
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline	1996
Selegiline and mortality in Parkinson's disease. Annals of neurology, 1996, Volume: 40, Issue:6 Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	1996
Parkinson's disease: diagnosis, pathology, and treatment. Journal of the Medical Association of Georgia, 1997, Volume: 86, Issue:2 Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline; Syndrome	1997
Neuroprotective therapy for Parkinson's disease. Experimental neurology, 1997, Volume: 144, Issue:1 Topics: Animals; Antiparkinson Agents; Humans; Infections; Mitochondria; MPTP Poisoning; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1997
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:1 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bupropion; Comorbidity; Depression; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline	1997
Attempts to obtain neuroprotection in Parkinson's disease. Neurology, 1997, Volume: 49, Issue:1 Suppl 1 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline	1997
Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology, 1997, Volume: 49, Issue:1 Suppl 1 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	1997
[Neuroprotective and neurorestorative therapy in Parkinson's disease]. Revista de neurologia, 1997, Volume: 25 Suppl 2 Topics: Antiparkinson Agents; Apoptosis; Brain Tissue Transplantation; Chelation Therapy; Corpus Striatum; Dopamine; Erythrocytes; Free Radicals; Gangliosides; Genetic Therapy; Glutathione Peroxidase; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Selegiline; Selenium; Vitamin E	1997
Early idiopathic parkinsonism: initiation and optimization of treatment. Clinical neuropharmacology, 1994, Volume: 17 Suppl 2 Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1994
Mid-stage parkinsonism with mild motor fluctuations. Clinical neuropharmacology, 1994, Volume: 17 Suppl 2 Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1994
Parkinson's disease: drug therapy. Bailliere's clinical neurology, 1997, Volume: 6, Issue:1 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	1997
Pregnancy in Parkinson's disease: a review of the literature and a case report. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline	1998
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacology & toxicology, 1998, Volume: 82, Issue:2 Topics: Animals; Antiparkinson Agents; Brain; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Catecholamine; Selegiline	1998
Free-radical toxicity and antioxidant medications in Parkinson's disease. Physical therapy, 1998, Volume: 78, Issue:3 Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Free Radicals; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Selegiline	1998
Neuroprotection by selegiline and other MAO inhibitors. Journal of neural transmission. Supplementum, 1998, Volume: 52 Topics: Animals; Antiparkinson Agents; Blood Pressure; Clinical Trials as Topic; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Posture; Prospective Studies; Selegiline	1998
The neuroprotective and neuronal rescue effects of (-)-deprenyl. Journal of neural transmission. Supplementum, 1998, Volume: 52 Topics: Animals; Antiparkinson Agents; Benzylamines; Biotransformation; Brain; Humans; Melanoma; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Rats; Selegiline; Tissue Distribution; Tumor Cells, Cultured	1998
Current status of selegiline as a neuroprotective agent in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13 Suppl 1 Topics: Antiparkinson Agents; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline	1998
Initiating therapy for Parkinson's disease. Neurology, 1998, Volume: 50, Issue:6 Suppl 6 Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1998
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug safety, 1998, Volume: 19, Issue:1 Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1998
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology, 1998, Volume: 51, Issue:3 Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline; Survival Rate	1998
Neuroprotection for Parkinson's disease. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required. BMJ (Clinical research ed.), 1998, Dec-05, Volume: 317, Issue:7172 Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Selegiline	1998
Free radicals in Alzheimer's dementia: currently available therapeutic strategies. Journal of neural transmission. Supplementum, 1998, Volume: 54 Topics: Alzheimer Disease; Antioxidants; Drugs, Chinese Herbal; Free Radical Scavengers; Free Radicals; Humans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Piperazines; Psychotropic Drugs; Selegiline; Thiophenes; Vitamins	1998
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality. BMJ (Clinical research ed.), 1998, Dec-05, Volume: 317, Issue:7172 Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline; Survival Analysis; Treatment Outcome	1998
Management of early Parkinson's disease. The Medical clinics of North America, 1999, Volume: 83, Issue:2 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Outcome	1999
Monoamine oxidase and catechol-O-methyltransferase inhibitors. The Medical clinics of North America, 1999, Volume: 83, Issue:2 Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Nitriles; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tolcapone	1999
Novel drugs for Parkinson's disease. The Medical clinics of North America, 1999, Volume: 83, Issue:2 Topics: Antiparkinson Agents; Biological Availability; Dopamine Agonists; Free Radical Scavengers; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	1999
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. PharmacoEconomics, 1992, Volume: 2, Issue:2 Topics: Cost of Illness; Humans; Levodopa; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome	1992
Current issues in depression in Parkinson's disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1999,Spring, Volume: 7, Issue:2 Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Parkinson Disease; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors; Selegiline	1999
Multiple antioxidants in the prevention and treatment of Parkinson's disease. Journal of the American College of Nutrition, 1999, Volume: 18, Issue:5 Topics: Animals; Antioxidants; Antiparkinson Agents; Humans; Mutation; Oxidative Stress; Parkinson Disease; Selegiline; Vitamins	1999
Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology (Budapest, Hungary), 1999, Volume: 7, Issue:2 Topics: Animals; Apoptosis; Humans; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinson Disease; Rats; Selegiline	1999
[Drug therapy of Parkinson's disease]. Duodecim; laaketieteellinen aikakauskirja, 1997, Volume: 113, Issue:18 Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	1997
[What strategies are recommended for early stage disease? Other treatments]. Revue neurologique, 2000, Volume: 156 Suppl 2 Pt 2 Topics: Amantadine; Antioxidants; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2000
(-)Deprenyl (Selegiline): past, present and future. Neurobiology (Budapest, Hungary), 2000, Volume: 8, Issue:2 Topics: Aging; Alzheimer Disease; Animals; Brain Chemistry; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2000
[Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:8 Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline	2001
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS drug reviews, 2001,Fall, Volume: 7, Issue:3 Topics: Aging; Alzheimer Disease; Animals; Benzofurans; Brain; Catecholamines; Depression; Humans; Neuroprotective Agents; Parkinson Disease; Propylamines; Selegiline; Serotonin	2001
Parkinson's disease therapy: treatment of early and late disease. Chinese medical journal, 2001, Volume: 114, Issue:3 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors	2001
Neuroprotective actions of selegiline. Journal of neuroscience research, 2002, Feb-01, Volume: 67, Issue:3 Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Selegiline; Treatment Outcome	2002
[Serotonin syndrome: report of a fatal case and review of the literature]. Revista clinica espanola, 2002, Volume: 202, Issue:4 Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome	2002
Recent advances in research on Parkinsonism. Acta neurologica Scandinavica. Supplementum, 1978, Volume: 67 Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase	1978
Parkinsonism treatment: Part III--Update. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:2 Topics: Antioxidants; Dopamine Agents; Female; Fetal Tissue Transplantation; Humans; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline; Vitamin E	1992
An integrated approach to patient management in Parkinson's disease. Neurologic clinics, 1992, Volume: 10, Issue:2 Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline	1992
Recent progress in the treatment of Parkinson's disease. Comprehensive therapy, 1992, Volume: 18, Issue:9 Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1992
Early therapy for Parkinson's disease. European neurology, 1992, Volume: 32 Suppl 1 Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline	1992
[Drug therapy of Parkinson disease]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1992, Oct-10, Volume: 112, Issue:24 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline	1992
[Current therapeutic approach in Parkinson disease]. Revue medicale de Bruxelles, 1992, Volume: 13, Issue:10 Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E	1992
[A drug ahead of its time: the success story of selegiline]. Acta pharmaceutica Hungarica, 1992, Volume: 62, Issue:5 Topics: Brain; Europe; Humans; Parkinson Disease; Selegiline; United States	1992
["Widening horizons" in the clinical application of selegiline]. Acta pharmaceutica Hungarica, 1992, Volume: 62, Issue:5 Topics: Alzheimer Disease; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1992
Neurotoxicity and neuroprotection in Parkinson's disease. Journal of neural transmission. Supplementum, 1992, Volume: 38 Topics: Antiparkinson Agents; Glutathione; Humans; Iron; Melanins; Mitochondria; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Selegiline; Substantia Nigra	1992
Neuroprotective clinical strategies for Parkinson's disease. Annals of neurology, 1992, Volume: 32 Suppl Topics: Drug Therapy, Combination; Humans; Iron; Oxidation-Reduction; Parkinson Disease; Selegiline; Vitamin E	1992
[Selegiline in Parkinson's disease; symptomatic or causal effect?]. Nederlands tijdschrift voor geneeskunde, 1992, Aug-08, Volume: 136, Issue:32 Topics: Energy Metabolism; Free Radicals; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	1992
Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1992, Volume: 19, Issue:1 Suppl Topics: Humans; Neurons; Parkinson Disease; Selegiline	1992
Treatment strategies for extension of levodopa effect. Neurologic clinics, 1992, Volume: 10, Issue:2 Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Selegiline	1992
Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. Neurologic clinics, 1992, Volume: 10, Issue:2 Topics: Humans; Monoamine Oxidase Inhibitors; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Substantia Nigra	1992
Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology, 1992, Volume: 42, Issue:4 Suppl 4 Topics: Double-Blind Method; Forecasting; Humans; Models, Neurological; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	1992
[The dopamine agonist, lisuride, in the therapy of Parkinson disease]. Acta histochemica. Supplementband, 1992, Volume: 42 Topics: Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline	1992
Selegiline--an overview of its role in the treatment of Parkinson's disease. The Clinical investigator, 1992, Volume: 70, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Monoamine Oxidase; Parkinson Disease; Selegiline	1992
The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacology & toxicology, 1992, Volume: 70, Issue:5 Pt 1 Topics: Alzheimer Disease; Animals; Brain; Humans; Parkinson Disease; Selegiline	1992
(-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. Journal of the American Geriatrics Society, 1992, Volume: 40, Issue:8 Topics: Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Parkinson Disease; Rats; Receptors, Dopamine; Selegiline; Substantia Nigra	1992
Antioxidative therapeutic strategies for Parkinson's disease. Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648 Topics: Antioxidants; Double-Blind Method; Free Radical Scavengers; Humans; Parkinson Disease; Selegiline; Vitamin E	1992
Parkinson's disease: management. Lancet (London, England), 1991, Jun-01, Volume: 337, Issue:8753 Topics: Basal Ganglia; Confounding Factors, Epidemiologic; Dopamine Agents; Humans; Parkinson Disease; Selegiline	1991
A review of the pharmacology of selegiline. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Levodopa; Monoamine Oxidase; Neurotransmitter Agents; Parkinson Disease; Selegiline; Survival Rate	1991
Parkinson's disease. Lancet (London, England), 1990, Apr-21, Volume: 335, Issue:8695 Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors	1990
Selegiline in the treatment of Parkinson's disease. The American journal of the medical sciences, 1991, Volume: 302, Issue:6 Topics: Humans; Parkinson Disease; Selegiline	1991
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs & aging, 1991, Volume: 1, Issue:3 Topics: Adult; Aged; Animals; Drug Interactions; Humans; Middle Aged; Parkinson Disease; Selegiline	1991
Monoamine oxidase, dopamine and Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Animals; Brain; Dopamine; Humans; Isoenzymes; Monoamine Oxidase; Neurologic Examination; Parkinson Disease; Selegiline	1991
Nigral degeneration in Parkinson's disease in relation to clinical features. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Corpus Striatum; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Neurologic Examination; Parkinson Disease; Selegiline; Substantia Nigra	1991
Selegiline hydrochloride and cognition. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Aged; Alzheimer Disease; Attention; Dementia; Depressive Disorder; Humans; Mental Recall; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Reaction Time; Selegiline	1991
New strategies in the treatment of early Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Brain; Drug Therapy, Combination; Humans; Isoenzymes; Monoamine Oxidase; Neurologic Examination; Parkinson Disease; Selegiline	1991
Selegiline: initial or adjunctive therapy of Parkinson's disease? DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:1 Topics: Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Parkinson Disease; Selegiline	1991
Deprenyl: protective vs. symptomatic effect. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1991, Volume: 18, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Humans; MPTP Poisoning; Parkinson Disease; Selegiline	1991
Deprenyl: the exciting possibility of protective effect. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1991, Volume: 18, Issue:1 Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1991
[New anti-parkinsonian drugs]. No to shinkei = Brain and nerve, 1991, Volume: 43, Issue:8 Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline	1991
Drug therapy for Parkinson's disease in the elderly. British medical bulletin, 1990, Volume: 46, Issue:1 Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1990
The modern management of Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:2 Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline	1990
[Slowing the progression of Parkinson syndrome by early administration of deprenyl]. Der Nervenarzt, 1990, Volume: 61, Issue:2 Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline	1990
Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs, 1990, Volume: 39, Issue:5 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1990
Selegiline HC1: Selective MAO-type B inhibitor. Neurology, 1990, Volume: 40, Issue:10 Suppl 3 Topics: Drug Administration Schedule; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1990
Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology, 1990, Volume: 40, Issue:10 Suppl 3 Topics: Brain; Free Radicals; Humans; Models, Neurological; Monoamine Oxidase; Neurotoxins; Oxygen; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Advances in neurology, 1990, Volume: 53 Topics: Aged; Animals; Corpus Striatum; Humans; Longevity; Male; Neural Pathways; Parkinson Disease; Rats; Receptors, Dopamine; Selegiline; Substantia Nigra	1990
[Protective therapy in Parkinson's disease]. Harefuah, 1990, Dec-16, Volume: 119, Issue:12 Topics: Animals; Humans; Levodopa; Pargyline; Parkinson Disease; Selegiline	1990
Parkinson's disease: new treatment strategies. Comprehensive therapy, 1990, Volume: 16, Issue:12 Topics: Adrenal Medulla; Animals; Brain Tissue Transplantation; Fetal Tissue Transplantation; Humans; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
Parkinson's disease update. Rhode Island medical journal, 1989, Volume: 72, Issue:11 Topics: Adrenal Medulla; Clinical Trials as Topic; Humans; Parkinson Disease; Selegiline; Vitamin E	1989
Selegiline in the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline	1989
Selegiline for parkinsonism--an update. Drug and therapeutics bulletin, 1989, Nov-27, Volume: 27, Issue:24 Topics: Humans; Parkinson Disease; Selegiline	1989
New perspectives in the treatment of Parkinson's disease. Clinical neuropharmacology, 1986, Volume: 9 Suppl 1 Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline; Sincalide	1986
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Journal of neural transmission. Supplementum, 1986, Volume: 20 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra	1986
The role of MAO in MPTP toxicity--a review. Journal of neural transmission. Supplementum, 1986, Volume: 20 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chemical Phenomena; Chemistry; Haplorhini; Hydrogen Peroxide; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroglia; Neurons; Oxidation-Reduction; Parkinson Disease; Pyridines; Rats; Selegiline; Species Specificity; Structure-Activity Relationship; Substrate Specificity	1986
Pharmacological approaches to Parkinson's disease in the different phases of evolution. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline	1986
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Animals; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tyramine	1986
Overview of the present state of MAO inhibitors. Journal of neural transmission. Supplementum, 1987, Volume: 23 Topics: Animals; Benzamides; Humans; Hydrazines; Isoquinolines; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Parkinson Disease; Phenethylamines; Piperidines; Selegiline; Structure-Activity Relationship	1987
'On-off' phenomenon: description, incidence and management. European neurology, 1987, Volume: 27 Suppl 1 Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline	1987
R-(-)-deprenyl and parkinsonism. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism	1987
Prevention of progression of Parkinson's disease with antioxidative therapy. Progress in neuro-psychopharmacology & biological psychiatry, 1988, Volume: 12, Issue:2-3 Topics: Antioxidants; Humans; Parkinson Disease; Selegiline; Vitamin E	1988
Controversies in the management of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1986, Volume: 1, Issue:3 Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1986
Deprenyl as symptomatic therapy in Parkinson's disease. Clinical neuropharmacology, 1988, Volume: 11, Issue:5 Topics: Antiparkinson Agents; Humans; Parkinson Disease; Phenethylamines; Selegiline	1988
Deprenyl as prophylaxis against Parkinson's disease? Clinical neuropharmacology, 1988, Volume: 11, Issue:6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; Phenethylamines; Pyridines; Selegiline	1988
The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mechanisms of ageing and development, 1985, May-13, Volume: 30, Issue:2 Topics: Aged; Aging; Animals; Brain; Depression; Dopamine; Geriatrics; Humans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Quality of Life; Rats; Selegiline; Sexual Behavior	1985
Update on the treatment of Parkinson's disease. Connecticut medicine, 1985, Volume: 49, Issue:10 Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors	1985

Trials

154 trial(s) available for selegiline and Idiopathic Parkinson Disease

Article	Year
Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. Parkinsonism & related disorders, 2022, Volume: 94 Topics: alpha-Tocopherol; Antiparkinson Agents; Humans; Parkinson Disease; Precision Medicine; Proteomics; Selegiline	2022
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:5 Topics: alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Predictive Value of Tests; Selegiline; Treatment Outcome; Vitamin B 12	2018
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta neuropathologica, 2013, Volume: 126, Issue:5 Topics: Adult; Aged; Amyloid beta-Peptides; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Selegiline; tau Proteins	2013
Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Double-Blind Method; Female; Humans; Incidence; Male; Melanoma; Middle Aged; National Institutes of Health (U.S.); Neuroprotective Agents; Parkinson Disease; Selegiline; Skin Neoplasms; United States; Young Adult	2014
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. The American journal of pathology, 2014, Volume: 184, Issue:4 Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; alpha-Tocopherol; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline	2014
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. Parkinsonism & related disorders, 2015, Volume: 21, Issue:3 Topics: Adult; Aged; Amyloid beta-Peptides; Antioxidants; Apolipoproteins E; Cognition Disorders; Cohort Studies; Cross-Sectional Studies; Female; Humans; Linear Models; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Peptide Fragments; Predictive Value of Tests; Selegiline; Severity of Illness Index; tau Proteins; Time Factors; Vitamin E	2015
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. The Lancet. Neurology, 2015, Volume: 14, Issue:8 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Medical Futility; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pioglitazone; Selegiline; Thiazolidinediones; Treatment Outcome	2015
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, Aug-12, Volume: 71, Issue:7 Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life; Selegiline	2008
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Movement disorders : official journal of the Movement Disorder Society, 2009, Dec-15, Volume: 24, Issue:16 Topics: Aged; Antioxidants; Cohort Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Tocopherols	2009
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. Journal of clinical pharmacology, 2010, Volume: 50, Issue:12 Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Humans; Hypertension; Indans; Isoenzymes; Male; Methoxyhydroxyphenylglycol; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tyramine; United States	2010
The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. Acta neurologica Scandinavica, 2011, Volume: 124, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Circulation Time; Brain; Cerebrovascular Circulation; Depressive Disorder; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Radionuclide Imaging; Selegiline; Treatment Outcome	2011
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism & related disorders, 2011, Volume: 17, Issue:2 Topics: Administration, Oral; Administration, Sublingual; Aged; Chemistry, Pharmaceutical; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Parkinson Disease; Selegiline; Treatment Outcome	2011
The effect of deprenyl washout in patients with long-standing Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:5-6 Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Double-Blind Method; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Psychiatric Status Rating Scales; Selegiline; Time Factors; Treatment Outcome	2002
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of neurology, 2002, Volume: 51, Issue:5 Topics: Aged; Antioxidants; Antiparkinson Agents; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Tocopherols; Treatment Outcome	2002
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism & related disorders, 2003, Volume: 9, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Supine Position	2003
Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. Journal of analytical toxicology, 2003, Volume: 27, Issue:3 Topics: Aged; Aged, 80 and over; Amphetamine; Amphetamines; Antiparkinson Agents; Drug Administration Schedule; Female; Hair; Hair Color; Humans; Male; Melanins; Methamphetamine; Middle Aged; Parkinson Disease; Patient Compliance; Selegiline; Spectrophotometry	2003
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology, 2003, Aug-12, Volume: 61, Issue:3 Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome	2003
L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Aged; Antiparkinson Agents; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Reaction Time; Selegiline	2003
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:11 Topics: Administration, Oral; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Satisfaction; Reference Values; Selegiline; Treatment Outcome; Tyramine	2003
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Movement Disorders; Parkinson Disease; Selegiline; Severity of Illness Index	2004
Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourology and urodynamics, 2004, Volume: 23, Issue:7 Topics: Adult; Antiparkinson Agents; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sex Characteristics; Surveys and Questionnaires; Urinary Bladder Diseases; Urination Disorders; Urodynamics; Urologic Diseases	2004
The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients. Acta neurologica Scandinavica, 2005, Volume: 111, Issue:2 Topics: Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Pulse; Rest; Selegiline; Supine Position	2005
Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome	2006
Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 2006, Apr-25, Volume: 66, Issue:8 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors	2006
Quality of life in Parkinson's disease--Indian scenario. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; India; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome	2006
Selegiline and blood pressure in patients with Parkinson's disease. Acta neurologica Scandinavica, 2007, Volume: 115, Issue:2 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; Parkinson Disease; Posture; Selegiline	2007
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Administration, Oral; Aged; Antiparkinson Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Polypharmacy; Selegiline; Tablets; Time Factors; Treatment Outcome	2007
Deprenyl in Parkinson disease. Neurology, 1981, Volume: 31, Issue:1 Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1981
Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. Modern problems of pharmacopsychiatry, 1983, Volume: 19 Topics: Amphetamine; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrogen-Ion Concentration; Parkinson Disease; Phenethylamines; Selegiline	1983
[Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study]. Orvosi hetilap, 1983, Sep-18, Volume: 124, Issue:38 Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Carboxy-Lyases; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1983
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. Journal of neurology, neurosurgery, and psychiatry, 1980, Volume: 43, Issue:11 Topics: Aged; Biotransformation; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1980
The effect of deprenyl and levodopa on the progression of Parkinson's disease. Annals of neurology, 1995, Volume: 38, Issue:5 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome	1995
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3 Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone	1995
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Archives of neurology, 1995, Volume: 52, Issue:6 Topics: Adult; Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors; Selegiline; Sex Factors; Vitamin E	1995
Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta neurologica Scandinavica, 1995, Volume: 91, Issue:3 Topics: Aged; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Random Allocation; Selegiline; Treatment Outcome	1995
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Annals of neurology, 1995, Volume: 37, Issue:1 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome	1995
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse (New York, N.Y.), 1994, Volume: 18, Issue:2 Topics: Aged; Brain; Female; Humans; Kinetics; Male; Middle Aged; Models, Biological; Monoamine Oxidase; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tomography, Emission-Computed	1994
Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology, 1995, Volume: 45, Issue:2 Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Carbidopa; Citrate (si)-Synthase; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Multienzyme Complexes; NAD(P)H Dehydrogenase (Quinone); Oxidoreductases; Parkinson Disease; Plateletpheresis; Selegiline; Succinate Dehydrogenase	1995
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Archives of neurology, 1995, Volume: 52, Issue:3 Topics: Adult; Aged; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Selegiline; Vitamin E	1995
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology, 1994, Volume: 44, Issue:9 Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline; Vitamin E	1994
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial. Internal medicine (Tokyo, Japan), 1994, Volume: 33, Issue:9 Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1994
Fluoxetine and selegiline--lack of significant interaction. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1994, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1994
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease]. No to shinkei = Brain and nerve, 1994, Volume: 46, Issue:5 Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1994
Visual control of arm movement in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1 Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline	1994
Die Pathoklise [Parkinson's disease]. Journal of neural transmission. Supplementum, 1993, Volume: 40 Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra	1993
Selegiline in de novo parkinsonian patients: the Finnish study. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Finland; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1993
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome	1993
Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta neurologica Scandinavica. Supplementum, 1993, Volume: 146 Topics: Aged; Disability Evaluation; Female; Humans; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1993
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. BMJ (Clinical research ed.), 1993, Aug-21, Volume: 307, Issue:6902 Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Treatment Outcome	1993
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The New England journal of medicine, 1993, Jan-21, Volume: 328, Issue:3 Topics: Activities of Daily Living; Arrhythmias, Cardiac; Follow-Up Studies; Humans; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance; Regression Analysis; Selegiline; Vitamin E	1993
Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clinical neuropharmacology, 1993, Volume: 16, Issue:1 Topics: Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Selegiline	1993
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ (Clinical research ed.), 1995, Dec-16, Volume: 311, Issue:7020 Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure	1995
L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study. Clinical neuropharmacology, 1995, Volume: 18, Issue:3 Topics: Aged; Antiparkinson Agents; Bromocriptine; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Parkinson Disease; Placebos; Prospective Studies; Selegiline	1995
Single vs multiple daily dosing of aminoglycosides. The Journal of family practice, 1996, Volume: 42, Issue:5 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Treatment Outcome	1996
Treatment of Parkinson's disease. The Journal of family practice, 1996, Volume: 42, Issue:5 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clinical neuropharmacology, 1995, Volume: 18, Issue:4 Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone	1995
Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Clinical neuropharmacology, 1995, Volume: 18, Issue:4 Topics: Aged; Cognition; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Selegiline; Time Factors	1995
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease]. No to shinkei = Brain and nerve, 1996, Volume: 48, Issue:5 Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1996
Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. European journal of clinical pharmacology, 1996, Volume: 50, Issue:1-2 Topics: Aged; Antiparkinson Agents; Arousal; Double-Blind Method; Female; Gait; Humans; Hypokinesia; Male; Muscle Rigidity; Parkinson Disease; Posture; Psychomotor Performance; Research Design; Selegiline; Treatment Outcome; Tremor	1996
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. Journal of neural transmission. Supplementum, 1995, Volume: 45 Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Methamphetamine; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1995
Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharmaceutics & drug disposition, 1995, Volume: 16, Issue:7 Topics: Adult; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Parkinson Disease; Selegiline; Time Factors	1995
DATATOP-study: significance of its results in the treatment of Parkinson's disease. Journal of neural transmission. Supplementum, 1995, Volume: 46 Topics: Antiparkinson Agents; Double-Blind Method; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Placebos; Selegiline	1995
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1996, Volume: 58, Issue:4 Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method	1996
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology, 1997, Volume: 48, Issue:3 Topics: Analysis of Variance; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Reflex; Selegiline; Tilt-Table Test	1997
The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Denmark; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease; Selegiline	1997
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:2 Topics: Activities of Daily Living; Adult; Aged; Antioxidants; Antiparkinson Agents; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome; Vitamin E	1997
Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. Journal of the neurological sciences, 1997, Feb-12, Volume: 145, Issue:2 Topics: Acylation; Aged; Antiparkinson Agents; Carnitine; Female; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Standards; Selegiline	1997
Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study. Acta neurologica Scandinavica, 1997, Volume: 95, Issue:4 Topics: Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Prospective Studies; Regression Analysis; Selegiline; Time Factors	1997
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:3 Topics: Adult; Aged; Antiparkinson Agents; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline	1997
Mortality associated with selegiline in Parkinson's disease. What do the available data mean? Drug safety, 1997, Volume: 16, Issue:5 Topics: Antiparkinson Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Prospective Studies; Research Design; Selegiline; United Kingdom	1997
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:4 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline	1997
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 63, Issue:2 Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline	1997
Moclobemide and selegeline in the treatment of depression in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 63, Issue:4 Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1997
Sertraline for the treatment of depression in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:5 Topics: 1-Naphthylamine; Aged; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Parkinson Disease; Pilot Projects; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Severity of Illness Index; Treatment Outcome	1997
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:6 Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index	1997
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Selegiline; Severity of Illness Index; Treatment Outcome	1998
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Annals of neurology, 1998, Volume: 43, Issue:3 Topics: Aged; Antiparkinson Agents; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline; Vitamin E	1998
Experience with tranylcypromine in early Parkinson's disease. Journal of neural transmission. Supplementum, 1998, Volume: 52 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders; Time Factors; Tranylcypromine; Tyramine	1998
Deprenyl monotherapy improves visuo-motor control in early parkinsonism. Journal of neural transmission. Supplementum, 1998, Volume: 52 Topics: Antiparkinson Agents; Female; Humans; Male; Motor Activity; Parkinson Disease; Psychomotor Performance; Selegiline; Severity of Illness Index	1998
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139 Topics: Antiparkinson Agents; Bromocriptine; Cause of Death; Disabled Persons; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Proportional Hazards Models; Selegiline; Survival Rate; Treatment Failure	1998
Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology, 1998, Volume: 50, Issue:6 Topics: Antioxidants; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Parkinson Disease; Selegiline; Vitamin E	1998
Mortality in people taking selegiline: observational study. BMJ (Clinical research ed.), 1998, Jul-25, Volume: 317, Issue:7153 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Follow-Up Studies; Humans; Middle Aged; Parkinson Disease; Risk Factors; Selegiline; Survival Rate; United Kingdom	1998
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:4 Topics: Administration, Oral; Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Pilot Projects; Selegiline; Tolcapone; Treatment Outcome	1998
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology, 1998, Volume: 51, Issue:2 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disabled Persons; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Probability; Selegiline; Time Factors	1998
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. European journal of neurology, 1999, Volume: 6, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors	1999
Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:2 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Blood Pressure; Dizziness; Drug Therapy, Combination; Epinephrine; Female; Head; Heart Rate; Humans; Hypotension, Orthostatic; Male; Middle Aged; Norepinephrine; Parkinson Disease; Posture; Prospective Studies; Selegiline; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors	1999
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:3 Topics: Aged; Antiparkinson Agents; Biological Transport; Carbidopa; Cocaine; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Monoamine Oxidase; Occipital Lobe; Parkinson Disease; Selegiline; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	1999
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Advances in neurology, 1999, Volume: 80 Topics: Adult; Aged; Benzamides; Cognition; Depression; Drug Combinations; Female; Humans; Male; Medical Records; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline	1999
Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. European journal of neurology, 1999, Volume: 6, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Denmark; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Norway; Parkinson Disease; Sample Size; Selegiline	1999
Effect of selegiline on cognitive functions in Parkinson's disease. The Journal of the Association of Physicians of India, 1999, Volume: 47, Issue:8 Topics: Adult; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Intelligence; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline	1999
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3 Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome	2000
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. Journal of neurology, 2000, Volume: 247, Issue:11 Topics: Aged; Blood Pressure; Bromocriptine; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	2000
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:2 Topics: Aged; Antiparkinson Agents; Bromocriptine; Female; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Selegiline; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome	2001
Suppressed sympathetic skin response in Parkinson disease. Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:6 Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System	2000
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology, 2001, Jun-26, Volume: 56, Issue:12 Topics: Aged; Double-Blind Method; Female; Gait; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Vitamin E	2001
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology, 2001, Nov-13, Volume: 57, Issue:9 Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome	2001
Zonisamide has beneficial effects on Parkinson's disease patients. Neuroscience research, 2001, Volume: 41, Issue:4 Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide	2001
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:2 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Placebo Effect; Selegiline; Tocopherols	2002
Experiences with L-deprenyl in Parkinsonism. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1978
A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group. Italian journal of neurological sciences, 1992, Volume: 13, Issue:9 Topics: Dopamine Agents; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Research Design; Selegiline; Severity of Illness Index	1992
An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. European neurology, 1992, Volume: 32 Suppl 1 Topics: Activities of Daily Living; Adult; Aged; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1992
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology, 1992, Volume: 42, Issue:3 Pt 1 Topics: Affect; Aged; Catalase; Free Radicals; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Superoxide Dismutase	1992
Antioxidative therapeutic strategies for Parkinson's disease. Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648 Topics: Antioxidants; Double-Blind Method; Free Radical Scavengers; Humans; Parkinson Disease; Selegiline; Vitamin E	1992
Selegiline as initial treatment in de novo parkinsonian patients. Neurology, 1992, Volume: 42, Issue:2 Topics: Aged; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1992
Selegiline in the treatment of Parkinson's disease. The American journal of the medical sciences, 1991, Volume: 302, Issue:6 Topics: Humans; Parkinson Disease; Selegiline	1991
Selegiline and cognitive function in Parkinson's disease. Acta neurologica Scandinavica, 1991, Volume: 84, Issue:5 Topics: Adult; Aged; Attention; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Selegiline	1991
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs & aging, 1991, Volume: 1, Issue:3 Topics: Adult; Aged; Animals; Drug Interactions; Humans; Middle Aged; Parkinson Disease; Selegiline	1991
Optoelectronic movement analysis in Parkinson's disease: effect of selegiline on the disability in de novo parkinsonian patients--a pilot study. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Aged; Disability Evaluation; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Selegiline; Video Recording	1991
Selegiline as a primary treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Activities of Daily Living; Double-Blind Method; Humans; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline	1991
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1991
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Adult; Aged; Brain; Disability Evaluation; Drug Therapy, Combination; Humans; Middle Aged; Monoamine Oxidase; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1991
Selegiline: initial or adjunctive therapy of Parkinson's disease? DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:1 Topics: Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Parkinson Disease; Selegiline	1991
DATATOP and clinical neuromythology IX. Neurology, 1991, Volume: 41, Issue:6 Topics: Humans; Parkinson Disease; Selegiline; Time Factors	1991
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clinical neuropharmacology, 1991, Volume: 14, Issue:3 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors	1991
Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta neurologica Scandinavica, 1991, Volume: 83, Issue:6 Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lisuride; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Selegiline	1991
Selegiline for Parkinson's disease. American family physician, 1990, Volume: 41, Issue:2 Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline	1990
Deprenyl and the progression of Parkinson's disease. Science (New York, N.Y.), 1990, Jul-20, Volume: 249, Issue:4966 Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline	1990
Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology, 1990, Volume: 40, Issue:10 Suppl 3 Topics: Brain; Free Radicals; Humans; Models, Neurological; Monoamine Oxidase; Neurotoxins; Oxygen; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients. Advances in neurology, 1990, Volume: 53 Topics: Aged; Carbidopa; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline	1990
Effects of L-deprenyl on parkinsonian bradyphrenia. Advances in neurology, 1990, Volume: 53 Topics: Adult; Attention; Cognition Disorders; Dementia; Double-Blind Method; Humans; Microcomputers; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline	1990
L-deprenyl therapy in Thai patients with Parkinson's disease: before and after, clinical trial of 50 patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1990, Volume: 73, Issue:7 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1990
The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology, 1989, Volume: 39, Issue:4 Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline	1989
Big first scored with nerve diseases. Science (New York, N.Y.), 1989, Aug-04, Volume: 245, Issue:4917 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra	1989
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (New York, N.Y.), 1989, Aug-04, Volume: 245, Issue:4917 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline	1989
Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology, 1989, Volume: 39, Issue:8 Topics: Adult; Aged; Analysis of Variance; Clinical Enzyme Tests; Clinical Trials as Topic; Double-Blind Method; Humans; Liver; Liver Function Tests; Middle Aged; Parkinson Disease; Phenethylamines; Safety; Selegiline; Time Factors	1989
Pergolide and selegiline for Parkinson's disease. The Medical letter on drugs and therapeutics, 1989, Sep-08, Volume: 31, Issue:800 Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Pergolide; Phenethylamines; Selegiline	1989
DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Archives of neurology, 1989, Volume: 46, Issue:10 Topics: Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline; Vitamin E	1989
Effect of deprenyl on the progression of disability in early Parkinson's disease. The New England journal of medicine, 1989, 11-16, Volume: 321, Issue:20 Topics: Activities of Daily Living; Clinical Trials as Topic; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline; Vitamin E	1989
Parkinson's disease update. Rhode Island medical journal, 1989, Volume: 72, Issue:11 Topics: Adrenal Medulla; Clinical Trials as Topic; Humans; Parkinson Disease; Selegiline; Vitamin E	1989
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Archives of neurology, 1989, Volume: 46, Issue:12 Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline	1989
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Archives of neurology, 1989, Volume: 46, Issue:12 Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline	1989
A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease. Clinical neuropharmacology, 1989, Volume: 12, Issue:5 Topics: Adjuvants, Pharmaceutic; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline	1989
Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline	1989
Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Adult; Aged; Antioxidants; Canada; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline; United States; Vitamin E	1989
Selegiline as primary treatment in early phase Parkinson's disease--an interim report. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline	1989
Multicenter trial of L-Deprenyl in Parkinson disease. Italian journal of neurological sciences, 1986, Volume: 7, Issue:1 Topics: Adult; Affect; Aged; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Tremor	1986
Drug trial for Parkinson's. Science (New York, N.Y.), 1987, Jun-12, Volume: 236, Issue:4807 Topics: Clinical Trials as Topic; Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1987
Adrenal-to-brain transplants continue as neurologists test two new drugs. JAMA, 1987, Aug-21, Volume: 258, Issue:7 Topics: Adrenal Glands; Caudate Nucleus; Clinical Trials as Topic; Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1987
Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial. Acta neurologica Scandinavica, 1987, Volume: 76, Issue:3 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Random Allocation; Selegiline	1987
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Self Concept	1987
Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Aged; Clinical Trials as Topic; Depression; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Thioxanthenes	1987
Current controversies in the use of selegiline hydrochloride. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Antidepressive Agents; Biomechanical Phenomena; Clinical Trials as Topic; Humans; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1987
R-(-)-deprenyl in the treatment of end-of-dose akinesia. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1987
R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline	1987
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Phenethylamines; Selegiline	1987
Deprenyl versus placebo in Parkinson disease: a double-blind study. New York state journal of medicine, 1987, Volume: 87, Issue:12 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1987
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clinical neuropharmacology, 1988, Volume: 11, Issue:1 Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline	1988
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial. Neurology, 1988, Volume: 38, Issue:9 Topics: Aged; Animals; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Selegiline	1988
The effect of L-Deprenyl on on-off phenomena in Parkinson's disease. Acta neurologica Scandinavica, 1985, Volume: 71, Issue:6 Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1985
Clinical trial for Parkinson's disease? Science (New York, N.Y.), 1985, Nov-01, Volume: 230, Issue:4725 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline	1985

Other Studies

371 other study(ies) available for selegiline and Idiopathic Parkinson Disease

Article	Year
Facile synthesis and in vitro properties of 1-alkyl- and 1-alkyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline derivatives on PC12 cells. European journal of medicinal chemistry, 2009, Volume: 44, Issue:10 Topics: Animals; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Monoamine Oxidase; Morphinans; Parkinson Disease; PC12 Cells; Rats; Structure-Activity Relationship; Tetrahydroisoquinolines	2009
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorganic & medicinal chemistry letters, 2009, Sep-01, Volume: 19, Issue:17 Topics: Coumarins; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Isoforms	2009
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1 Topics: Amines; Animals; Antiparkinson Agents; Cells, Cultured; Humans; Memantine; Molecular Structure; Neurons; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis	2010
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B. European journal of medicinal chemistry, 2012, Volume: 48 Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dynamics Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Conformation; Structure-Activity Relationship; Tandem Mass Spectrometry; Thiazoles	2012
Selected chromone derivatives as inhibitors of monoamine oxidase. Bioorganic & medicinal chemistry letters, 2012, Sep-01, Volume: 22, Issue:17 Topics: Benzopyrans; Chromones; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Parkinson Disease; Protein Isoforms; Recombinant Proteins; Structure-Activity Relationship	2012
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. Bioorganic & medicinal chemistry, 2013, Sep-01, Volume: 21, Issue:17 Topics: Binding Sites; Catalytic Domain; Dopamine; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxazoles; Parkinson Disease; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Thiazoles	2013
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4 Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics	2015
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. Journal of medicinal chemistry, 2016, 07-14, Volume: 59, Issue:13 Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quinoxalines; Rats, Sprague-Dawley; Structure-Activity Relationship	2016
Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship; Styrenes	2017
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. European journal of medicinal chemistry, 2018, Jan-01, Volume: 143 Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Humans; Hydrazones; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship	2018
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy. Bioorganic & medicinal chemistry, 2018, 01-01, Volume: 26, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship	2018
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors. Bioorganic & medicinal chemistry, 2018, 11-01, Volume: 26, Issue:20 Topics: Chemistry Techniques, Synthetic; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quinazolinones; Structure-Activity Relationship	2018
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease. European journal of medicinal chemistry, 2019, Jul-01, Volume: 173 Topics: Animals; Coumarins; Dose-Response Relationship, Drug; Drug Discovery; Humans; Inflammation; Male; Mannich Bases; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship; Tumor Cells, Cultured	2019
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. Bioorganic & medicinal chemistry letters, 2022, 07-01, Volume: 67 Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propylamines; Selegiline; Tetrahydronaphthalenes; Tyramine	2022
Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles. Bioorganic & medicinal chemistry letters, 2022, 10-15, Volume: 74 Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship	2022
The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update. CNS & neurological disorders drug targets, 2023, Volume: 22, Issue:3 Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Parkinson Disease; Selegiline	2023
Selegiline improves excessive daytime sleepiness in Parkinson's disease: an open-label observational study. Chinese medical journal, 2022, 07-20, Volume: 135, Issue:14 Topics: Disorders of Excessive Somnolence; Humans; Parkinson Disease; Selegiline; Severity of Illness Index	2022
The Relationship between Procyanidin Structure and Their Protective Effect in a Parkinson's Disease Model. Molecules (Basel, Switzerland), 2022, Aug-06, Volume: 27, Issue:15 Topics: 1-Methyl-4-phenylpyridinium; Animals; Biflavonoids; Catechin; Oxidative Stress; Parkinson Disease; Proanthocyanidins; Rats; Selegiline; Zebrafish	2022
Platelet abnormalities in patients with Parkinson's disease undergoing preoperative evaluation for deep brain stimulation. Scientific reports, 2022, 08-26, Volume: 12, Issue:1 Topics: Blood Platelet Disorders; Deep Brain Stimulation; Hemostatics; Humans; Parkinson Disease; Selegiline; Treatment Outcome	2022
Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3 Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2023
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On. Journal of integrative neuroscience, 2022, Oct-08, Volume: 21, Issue:6 Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2022
Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease. International journal of molecular sciences, 2023, Aug-07, Volume: 24, Issue:15 Topics: Acetylcysteine; Aldehyde Dehydrogenase; Animals; Dopamine; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Rotenone; Selegiline	2023
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system. Scientific reports, 2023, 11-06, Volume: 13, Issue:1 Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline	2023
Selegiline reduces daytime sleepiness in patients with Parkinson's disease. Brain and behavior, 2021, Volume: 11, Issue:5 Topics: Disorders of Excessive Somnolence; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Retrospective Studies; Selegiline	2021
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. Journal of neurology, 2017, Volume: 264, Issue:6 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Follow-Up Studies; Humans; Indans; Italy; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index	2017
Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease. Molecular neurobiology, 2018, Volume: 55, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Lipopolysaccharides; Nerve Tissue Proteins; Neuroblastoma; Parkinson Disease; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Selegiline; Sulfonamides	2018
Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease. Current drug discovery technologies, 2019, Volume: 16, Issue:4 Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Catalase; Catalepsy; Chitosan; Chlorpromazine; Female; Glutathione; Male; Nanoparticles; Nitrites; Parkinson Disease; Rats, Wistar; Selegiline; Thiobarbituric Acid Reactive Substances	2019
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. Rejuvenation research, 2018, Volume: 21, Issue:5 Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Compounding; Haloperidol; Male; Nanoparticles; Oxidative Stress; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Up-Regulation	2018
Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:8 Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Behavior, Animal; Biological Availability; Brain; Chitosan; Disease Models, Animal; Drug Carriers; Drug Liberation; Male; Nanoparticles; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Tissue Distribution	2018
Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease. Central nervous system agents in medicinal chemistry, 2019, Volume: 19, Issue:1 Topics: Administration, Intranasal; Animals; Disease Management; Drug Carriers; Drug Delivery Systems; Drug Development; Lipids; Male; Nanostructures; Nasal Mucosa; Parkinson Disease; Rats; Rats, Wistar; Selegiline	2019
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular medicine, 2019, Volume: 21, Issue:3 Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline	2019
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Irish medical journal, 2013, Volume: 106, Issue:1 Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline	2013
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:5 Topics: Administration, Oral; Amphetamine; Biological Availability; Drug Evaluation; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tablets	2013
[Primary prevention with enhancer substances for a longer and healthier life]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2013, Volume: 15, Issue:2 Topics: Aging; Antiparkinson Agents; Chronic Disease; Disease Progression; Education, Medical; Feeding Behavior; Humans; Hungary; Life Expectancy; Life Style; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Primary Prevention; Secondary Prevention; Selegiline; Tertiary Prevention	2013
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease. International journal of molecular medicine, 2013, Volume: 32, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Disease Models, Animal; Dopaminergic Neurons; Gait; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Real-Time Polymerase Chain Reaction; RNA, Messenger; Selegiline	2013
Zoophilia and Parkinson's disease. Parkinsonism & related disorders, 2013, Volume: 19, Issue:12 Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological	2013
A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time. Statistics in medicine, 2014, Feb-20, Volume: 33, Issue:4 Topics: Bayes Theorem; Computer Simulation; Disease Progression; Drug Therapy, Combination; Humans; Longitudinal Studies; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tocopherols	2014
C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl. Journal of neural transmission (Vienna, Austria : 1996), 2014, Volume: 121, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Natriuretic Peptide, C-Type; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index; Time Factors	2014
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PloS one, 2014, Volume: 9, Issue:1 Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine Agents; Hallucinations; Humans; Illusions; Levodopa; Logistic Models; Multivariate Analysis; Parkinson Disease; Psychotic Disorders; Risk Factors; Selegiline; Surveys and Questionnaires	2014
Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil. Drug development and industrial pharmacy, 2014, Volume: 40, Issue:5 Topics: Acrylic Resins; Administration, Buccal; Animals; Antiparkinson Agents; Cell Line; Chemistry, Pharmaceutical; Cysteine; Delayed-Action Preparations; Humans; Mice; Monoamine Oxidase Inhibitors; Oral Mucosal Absorption; Parkinson Disease; Selegiline; Tablets; Tensile Strength	2014
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacological reports : PR, 2014, Volume: 66, Issue:3 Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine	2014
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:2 Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase	2015
Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease. Statistics in medicine, 2014, Oct-30, Volume: 33, Issue:24 Topics: Bayes Theorem; Clinical Trials as Topic; Computer Simulation; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Multivariate Analysis; Parkinson Disease; Selegiline; Survival Analysis; Tocopherols	2014
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:22 Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2014
Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation. Nature communications, 2014, Dec-19, Volume: 5 Topics: alpha-Synuclein; Antiparkinson Agents; Humans; Indoles; Parkinson Disease; Protein Aggregation, Pathological; Protein Folding; Protein Stability; Protein Structure, Secondary; Selegiline; Synaptic Vesicles	2014
[Neurological common diseases in the super-elder society. Topics: IV. Parkinson's disease; 2. Current and new drugs for initial treatment of Parkinson's disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Aug-10, Volume: 103, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	2014
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report]. Rinsho shinkeigaku = Clinical neurology, 2015, Volume: 55, Issue:3 Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline	2015
Autophagy-related protein expression in the substantia nigra and eldepryl intervention in rat models of Parkinson's disease. Brain research, 2015, Nov-02, Volume: 1625 Topics: Animals; Apoptosis Regulatory Proteins; Beclin-1; Disease Models, Animal; Insecticides; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Time Factors	2015
Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:2 Topics: Aged; Antiparkinson Agents; Female; Health Care Costs; Hospitalization; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	2016
Robust Bayesian hierarchical model using normal/independent distributions. Biometrical journal. Biometrische Zeitschrift, 2016, Volume: 58, Issue:4 Topics: Bayes Theorem; Biometry; Disease Progression; Humans; Longitudinal Studies; Models, Statistical; Normal Distribution; Parkinson Disease; Selegiline	2016
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. Journal of Parkinson's disease, 2016, 04-02, Volume: 6, Issue:2 Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome	2016
Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease. European neurology, 2016, Volume: 76, Issue:1-2 Topics: Aged; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Muscular Atrophy, Spinal; Parkinson Disease; Selegiline; Spinal Curvatures; Treatment Outcome	2016
Bradykinesia in early and advanced Parkinson's disease. Journal of the neurological sciences, 2016, Oct-15, Volume: 369 Topics: Aged; Biomechanical Phenomena; Case-Control Studies; Female; Humans; Hypokinesia; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Selegiline; Severity of Illness Index	2016
Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease. Nanotechnology, 2016, Oct-28, Volume: 27, Issue:43 Topics: Animals; Behavior, Animal; Emulsions; Nanostructures; Olfactory Bulb; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Solubility	2016
Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson's disease. Neurological research, 2017, Volume: 39, Issue:5 Topics: Analysis of Variance; Animals; CD11b Antigen; Cell Proliferation; Corpus Striatum; Disease Models, Animal; Glial Fibrillary Acidic Protein; Male; Neuroglia; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra; Time Factors	2017
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2017, Volume: 124, Issue:6 Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome	2017
1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochemistry international, 2008, Volume: 53, Issue:6-8 Topics: 1-Methyl-4-phenylpyridinium; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Herbicides; Humans; JNK Mitogen-Activated Protein Kinases; Lipid Peroxidation; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Phosphorylation; Proteins; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Selegiline; Serine; Signal Transduction	2008
Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2008, Volume: 128, Issue:10 Topics: Adult; Amphetamine; Biomarkers; Drug Overdose; Gas Chromatography-Mass Spectrometry; Humans; Male; Methamphetamine; Parkinson Disease; Selegiline; Suicide, Attempted	2008
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Fortschritte der Neurologie-Psychiatrie, 2008, Volume: 76, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome	2008
Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:16 Topics: Drug Tolerance; Humans; Integrative Medicine; Parkinson Disease; Selegiline; Treatment Outcome	2008
Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:11 Topics: Animals; Antiparkinson Agents; Biomarkers; Cell Survival; Female; Genomics; Indans; Nerve Growth Factors; Nerve Tissue Proteins; Neurogenesis; Neuroprotective Agents; Parkinson Disease; Proteomics; Rats; Rats, Wistar; Selegiline; Signal Transduction; Substantia Nigra	2009
Selegiline shortage: Causes and costs of a generic drug shortage. Neurology, 2009, Jul-21, Volume: 73, Issue:3 Topics: Antiparkinson Agents; Drug and Narcotic Control; Drug Costs; Drug Industry; Drugs, Generic; Health Services Accessibility; Humans; Parkinson Disease; Prescriptions; Selegiline	2009
Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cellular and molecular neurobiology, 2010, Volume: 30, Issue:3 Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Blotting, Western; Brain; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cytoprotection; Gyrus Cinguli; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Selegiline; Triazoles; Up-Regulation	2010
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology, 2009, Nov-03, Volume: 73, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Cognition Disorders; Female; Gastrointestinal Tract; Humans; Incidence; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Risk Assessment; Risk Factors; Selection Bias; Selegiline; Tocopherols; United States; Urogenital System	2009
[General anaesthesia for neurological diseases]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2010, Volume: 45, Issue:5 Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome	2010
Clozapine for medication-related pathological gambling in Parkinson disease. Movement disorders : official journal of the Movement Disorder Society, 2010, Sep-15, Volume: 25, Issue:12 Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Clozapine; Ergolines; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline; Serotonin Antagonists	2010
Slowing the decline. Nature, 2010, Aug-26, Volume: 466, Issue:7310 Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegiline; Ubiquinone	2010
Ring opening of pymisyl-protected aziridines with organocuprates. Chemistry (Weinheim an der Bergstrasse, Germany), 2010, Nov-02, Volume: 16, Issue:41 Topics: Aziridines; Combinatorial Chemistry Techniques; Copper; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organometallic Compounds; Parkinson Disease; Selegiline; Stereoisomerism; Sulfhydryl Compounds; Sulfonamides	2010
The fabulous neuroprotection of selegiline: memoir and prospectus. Journal of child neurology, 2010, Volume: 25, Issue:10 Topics: Antiparkinson Agents; Forecasting; History, 20th Century; History, 21st Century; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2010
Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism & related disorders, 2011, Volume: 17, Issue:3 Topics: Aged; Disability Evaluation; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Proportional Hazards Models; Psychiatric Status Rating Scales; Selegiline	2011
Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson's disease in Phramongkutklao Hospital. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93 Suppl 6 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Cross-Sectional Studies; Female; Hospitals, Teaching; Humans; Hypotension, Orthostatic; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Polypharmacy; Posture; Risk Factors; Selegiline; Severity of Illness Index; Time Factors	2010
MAO inhibitors. Cleveland Clinic journal of medicine, 2011, Volume: 78, Issue:2 Topics: Depression; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2011
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain research, 2011, Aug-23, Volume: 1408 Topics: Adult; Age of Onset; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkinson Disease; Purines; Selegiline; Xanthine; Young Adult	2011
Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PloS one, 2011, Volume: 6, Issue:8 Topics: Antioxidants; Cholesterol; Disease Progression; Endpoint Determination; Female; Humans; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Randomized Controlled Trials as Topic; Selegiline; Tocopherols	2011
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor	2012
8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. ChemMedChem, 2012, Mar-05, Volume: 7, Issue:3 Topics: Alzheimer Disease; Coumarins; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Binding; Protein Isoforms; Selegiline; Solutions	2012
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome	2012
Cerebral blood flow and freezing of gait in Parkinson's disease. Acta neurologica Scandinavica, 2012, Volume: 126, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Circulation; Disability Evaluation; Drug Therapy, Combination; Female; Gait Disorders, Neurologic; Humans; Iofetamine; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Selegiline; Tomography, Emission-Computed, Single-Photon	2012
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology, 2012, Jun-12, Volume: 78, Issue:24 Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Precision Medicine; Selegiline; Subthalamic Nucleus; Treatment Outcome	2012
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012, Volume: 19, Issue:9 Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline	2012
Retention rate of selegiline in early Parkinson's disease: a retrospective survey. International journal of clinical practice, 2012, Volume: 66, Issue:10 Topics: Antiparkinson Agents; Humans; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline	2012
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:5 Topics: Aged; Amphetamine; Antiparkinson Agents; Drug Substitution; Female; Humans; Indans; Male; Methamphetamine; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Selegiline; Severity of Illness Index; Time Factors	2013
Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire international, 2002, Volume: 11, Issue:60 Topics: Antiparkinson Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; France; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Treatment Outcome	2002
The multiple actions of selegiline. Proceedings of the Western Pharmacology Society, 2002, Volume: 45 Topics: Animals; Antiparkinson Agents; Cells, Cultured; Dopamine; Female; Glutamic Acid; Mesencephalon; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline	2002
[Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment]. No to shinkei = Brain and nerve, 2002, Volume: 54, Issue:12 Topics: Aged; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	2002
Neuroprotection for Parkinson's disease: prospects and promises. Annals of neurology, 2003, Volume: 53 Suppl 3 Topics: Amphetamines; Clinical Trials as Topic; Glial Cell Line-Derived Neurotrophic Factor; Humans; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Selegiline	2003
A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life sciences, 2003, Apr-25, Volume: 72, Issue:23 Topics: alpha-Tocopherol; Animals; Benzofurans; Brain; Dopamine; In Vitro Techniques; Male; Monoamine Oxidase Inhibitors; Norepinephrine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Treatment Failure	2003
Monoamine oxidase inhibitors--is it time to up the TEMPO? The Lancet. Neurology, 2003, Volume: 2, Issue:3 Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome	2003
[Therapy for patients with early-stage Parkinson's disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8 Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl	2003
Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects. Prescrire international, 2003, Volume: 12, Issue:67 Topics: Administration, Sublingual; Antiparkinson Agents; Clinical Trials as Topic; Humans; Oral Ulcer; Parkinson Disease; Selegiline	2003
Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. Neurotoxicology, 2004, Volume: 25, Issue:1-2 Topics: Animals; Disease Models, Animal; Dopamine; Encephalitis Virus, Japanese; Hypokinesia; Isatin; Mice; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Selegiline	2004
Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. Parkinsonism & related disorders, 2004, Volume: 10, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Female; Hallucinations; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Statistics, Nonparametric	2004
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Consciousness Disorders; Dantrolene; Deep Brain Stimulation; Diagnosis, Differential; Diagnostic Errors; Dystonic Disorders; Encephalitis; Female; Fluid Therapy; Foot; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Muscle Relaxants, Central; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tachycardia	2004
Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum. Parkinsonism & related disorders, 2004, Volume: 10, Issue:7 Topics: Adolescent; Antiparkinson Agents; Benztropine; Cognition Disorders; Corpus Callosum; Electroencephalography; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Weakness; Neuropsychological Tests; Parkinson Disease; Selegiline; Spastic Paraplegia, Hereditary; Tremor	2004
Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:12 Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain Chemistry; Cell Line, Tumor; Dopamine; Dose-Response Relationship, Drug; Humans; Indoles; Melanins; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Selegiline; Tryptamines	2004
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology, 2005, Jan-11, Volume: 64, Issue:1 Topics: Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Likelihood Functions; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Selegiline; Survival Analysis; Time; Tocopherols	2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology, 2005, Mar-08, Volume: 64, Issue:5 Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome	2005
Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. Parkinsonism & related disorders, 2005, Volume: 11, Issue:4 Topics: Antiparkinson Agents; Hallucinations; Humans; Parkinson Disease; Selegiline	2005
Reexamination of the TEMPO Study. Archives of neurology, 2005, Volume: 62, Issue:8 Topics: Antioxidants; Antiparkinson Agents; Artifacts; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Selegiline; Treatment Outcome	2005
Rasagiline. Nature reviews. Drug discovery, 2005, Volume: 4, Issue:8 Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Industry; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	2005
Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, Mar-07, Volume: 103, Issue:10 Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Line; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; In Vitro Techniques; Male; Mice; MPTP Poisoning; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide; Nuclear Proteins; Oxepins; Parkinson Disease; Selegiline; Ubiquitin-Protein Ligases	2006
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. Journal of pharmacokinetics and pharmacodynamics, 2006, Volume: 33, Issue:3 Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2006
Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology, 2006, May-09, Volume: 66, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Databases, Factual; Dementia; Dopamine Agonists; Drug Prescriptions; Drug Utilization; Geriatrics; Humans; Levodopa; Male; Medicine; Middle Aged; Neurology; Northwestern United States; Parkinson Disease; Practice Patterns, Physicians'; Primary Health Care; Psychiatry; Psychology; Retrospective Studies; Selegiline; Specialization; United States; United States Department of Veterans Affairs; Veterans	2006
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology, 2006, May-23, Volume: 66, Issue:10 Suppl 4 Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Selegiline; Treatment Outcome	2006
Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism & related disorders, 2006, Volume: 12, Issue:6 Topics: Antiparkinson Agents; Compulsive Behavior; Erotica; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Personality Disorders; Psychiatric Status Rating Scales; Selegiline; Sexual Dysfunctions, Psychological	2006
Transdermal selegiline (Emsam). The Medical letter on drugs and therapeutics, 2006, May-22, Volume: 48, Issue:1235 Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2006
High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. Journal of analytical toxicology, 2006, Volume: 30, Issue:4 Topics: Amphetamine; Amphetamines; Antiparkinson Agents; Chromatography, High Pressure Liquid; Hair; Humans; Methamphetamine; Parkinson Disease; Selegiline; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection	2006
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2006, Volume: 13, Issue:8 Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries	2006
Low plasma uric acid level in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2007, Jun-15, Volume: 22, Issue:8 Topics: Aged; Antiparkinson Agents; Body Mass Index; Energy Intake; Female; Ferritins; Humans; Levodopa; Male; Mass Screening; Middle Aged; Parkinson Disease; Plasma; Risk Factors; Selegiline; Spouses; Uric Acid	2007
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs. Metabolic brain disease, 2009, Volume: 24, Issue:4 Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain Diseases; Cell Line, Tumor; Clorgyline; Endocytosis; Exocytosis; Hydrogen-Ion Concentration; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organelles; Pargyline; Parkinson Disease; Protons; Selegiline; Signal Transduction; Transport Vesicles	2009
Rasagiline as a therapy for Parkinson's disease (PD). The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:2 Topics: Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2007
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. Journal of neural transmission. Supplementum, 2007, Issue:72 Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Membrane Potentials; Mitochondria; Neuroblastoma; Neuroprotective Agents; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins c-bcl-2; Selegiline	2007
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5 Topics: Activities of Daily Living; Aged; Canada; Cognition Disorders; Cohort Studies; Depressive Disorder; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Psychological Tests; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Tocopherols; United States	2008
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic. Journal of psychiatric practice, 2008, Volume: 14, Issue:1 Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl	2008
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Ideggyogyaszati szemle, 2008, Jan-30, Volume: 61, Issue:1-2 Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome	2008
Deprenyl in Parkinson's disease. Lancet (London, England), 1982, Sep-25, Volume: 2, Issue:8300 Topics: Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline	1982
Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1984, Volume: 11, Issue:1 Suppl Topics: Adrenergic beta-Antagonists; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine; Dopamine Antagonists; Humans; Lithium; Neurology; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Selegiline; Serotonin; Sympathomimetics	1984
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Aging; Alzheimer Disease; Brain; Central Nervous System; Female; Humans; Huntington Disease; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phenethylamines; Selegiline	1983
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. Journal of neural transmission. Supplementum, 1983, Volume: 19 Topics: Animals; Brain; Catalase; Catecholamines; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Levodopa; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Selegiline; Superoxide Dismutase; Superoxides	1983
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. Advances in neurology, 1983, Volume: 37 Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Lisuride; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tranylcypromine	1983
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Modern problems of pharmacopsychiatry, 1983, Volume: 19 Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1983
[The use of L-deprenyl in Parkinson's disease]. Zhonghua yi xue za zhi, 1983, Volume: 63, Issue:3 Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Advances in neurology, 1984, Volume: 40 Topics: Animals; Brain Chemistry; Dextroamphetamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline; Stereotyped Behavior	1984
Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease. Advances in neurology, 1984, Volume: 40 Topics: Benzamides; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Tiapamil Hydrochloride	1984
Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. Journal of neural transmission. Supplementum, 1983, Volume: 19 Topics: Aged; Disability Evaluation; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline	1983
L-deprenyl in the treatment of Parkinson's disease. Journal of neural transmission. Supplementum, 1983, Volume: 19 Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor. New York state journal of medicine, 1984, Volume: 84, Issue:1 Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1984
Why another anti-Parkinson drug? Nursing mirror, 1984, Feb-29, Volume: 158, Issue:9 Topics: Aged; Antiparkinson Agents; Humans; Parkinson Disease; Phenethylamines; Selegiline	1984
A new approach to the treatment of Parkinson's disease. Symposium, Turku, Finland, May 27, 1983. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Outcome and Process Assessment, Health Care; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1983
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Amphetamine; Humans; Hydrogen-Ion Concentration; Methamphetamine; Parkinson Disease; Phenethylamines; Selegiline	1983
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1983
Deprenyl (selegiline) in combination treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1983
The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Arousal; Behavior; Cognition; Drug Therapy, Combination; Emotions; Female; Humans; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1983
Monoamine oxidase inhibitors and their pharmacological significance. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Animals; Antidepressive Agents; Brain; Clorgyline; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Rats; Selegiline; Tyramine	1983
Deprenyl (selegiline): the history of its development and pharmacological action. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aging; Animals; Brain; Depression; Dopamine; Drug Evaluation; History, 20th Century; Humans; Male; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Sexual Behavior	1983
Dose regimen of deprenyl (selegiline) and platelet MAO activities. Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Blood Platelets; Dose-Response Relationship, Drug; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline	1983
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline). Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Drug Therapy, Combination; Humans; Levodopa; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors	1983
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease. British journal of clinical pharmacology, 1980, Volume: 9, Issue:1 Topics: Aged; Brain Chemistry; Dopamine; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; Phenethylamines; Selegiline; Serotonin	1980
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study. Progress in clinical and biological research, 1980, Volume: 39 Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor	1980
Biochemical characterization of the active site of brain monoamine oxidase. Monographs in neural sciences, 1980, Volume: 7 Topics: Antidepressive Agents; Binding Sites; Brain; Clorgyline; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Binding; Selegiline; Substrate Specificity; Tissue Distribution	1980
Deprenyl does not cause insomnia in parkinsonian patients. Communications in psychopharmacology, 1980, Volume: 4, Issue:4 Topics: Aged; Electroencephalography; Humans; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sleep; Sleep Initiation and Maintenance Disorders	1980
Deprenyl in Parkinson disease. Neurology, 1981, Volume: 31, Issue:12 Topics: False Negative Reactions; Humans; Parkinson Disease; Phenethylamines; Selegiline	1981
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology, 1982, Volume: 32, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine	1982
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. Journal of neural transmission, 1982, Volume: 54, Issue:1-2 Topics: Amphetamine; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Levodopa; Methamphetamine; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1982
(-)Deprenyl in the treatment of Parkinson's disease. Clinical neuropharmacology, 1982, Volume: 5, Issue:2 Topics: 5-Hydroxytryptophan; Brain; Dopamine; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin	1982
[Initiation of treatment in Parkinson disease]. Praxis, 1995, Sep-19, Volume: 84, Issue:38 Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline	1995
Treatment of Parkinson's disease. Australian family physician, 1995, Volume: 24, Issue:9 Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline	1995
Clinical and [18F] dopa PET findings in early Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1995, Volume: 59, Issue:6 Topics: Antiparkinson Agents; Case-Control Studies; Dihydroxyphenylalanine; Discriminant Analysis; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Putamen; Selegiline; Severity of Illness Index; Time Factors; Tomography, Emission-Computed	1995
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. Journal of neurochemistry, 1995, Volume: 65, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra	1995
Selegiline, fluoxetine, and depression in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3 Topics: Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline	1995
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease. Clinical neurology and neurosurgery, 1995, Volume: 97, Issue:2 Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome	1995
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. Journal of neural transmission. General section, 1994, Volume: 98, Issue:1 Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline	1994
[Pseudopheochromocytoma in a parkinsonian patient treated with selegiline]. La Revue de medecine interne, 1995, Volume: 16, Issue:3 Topics: Aged; Diagnosis, Differential; Female; Humans; Parkinson Disease; Pheochromocytoma; Selegiline	1995
Parkinson's disease. Postgraduate medical journal, 1995, Volume: 71, Issue:834 Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1995
Role of selegiline as initial monotherapy in early Parkinson's disease. The Journal of the Association of Physicians of India, 1994, Volume: 42, Issue:1 Topics: Activities of Daily Living; Drug Tolerance; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Safety; Selegiline; Time Factors; Tremor	1994
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes. Journal of neural transmission. General section, 1994, Volume: 96, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liquid; Clorgyline; Corpus Striatum; Dopamine; Isoquinolines; Monoamine Oxidase; NAD; Nerve Tissue Proteins; Nomifensine; Parkinson Disease; Rats; Selegiline; Sulpiride; Synaptosomes; Tyrosine 3-Monooxygenase	1994
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning. Neuropsychologia, 1994, Volume: 32, Issue:11 Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception	1994
Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clinical endocrinology, 1995, Volume: 42, Issue:1 Topics: Bronchial Spasm; Bronchitis; Depressive Disorder; Diagnosis, Differential; Drug Interactions; Ephedrine; Epinephrine; Humans; Hypertension; Male; Maprotiline; Middle Aged; Norepinephrine; Parkinson Disease; Pheochromocytoma; Selegiline	1995
[Bromocriptine-induced pleuropneumopathy]. Deutsche medizinische Wochenschrift (1946), 1994, Nov-11, Volume: 119, Issue:45 Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors	1994
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet (London, England), 1993, Feb-27, Volume: 341, Issue:8844 Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Diagnosis, Differential; Drug Interactions; Female; Fluoxetine; Humans; Hypertension; Parkinson Disease; Pheochromocytoma; Selegiline	1993
Drugs for Parkinson's disease. The Medical letter on drugs and therapeutics, 1993, Apr-16, Volume: 35, Issue:894 Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1993
Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism. Progress in neuro-psychopharmacology & biological psychiatry, 1994, Volume: 18, Issue:1 Topics: Aged; Attention; Female; Frontal Lobe; Humans; Language; Learning; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline; Space Perception; Verbal Learning	1994
Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:2 Topics: Humans; Parkinson Disease; Research Design; Selegiline; Time Factors; Treatment Outcome	1994
Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted? Journal of clinical pharmacology, 1994, Volume: 34, Issue:1 Topics: Aged; Computer Simulation; DNA; Glucose; Humans; Hypoglycemia; Insulin; Male; Monoamine Oxidase Inhibitors; Nucleic Acid Conformation; Parkinson Disease; Selegiline	1994
Deprenyl and the issue of neuroprotection. European neurology, 1994, Volume: 34, Issue:1 Topics: Antioxidants; Cell Survival; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Neurons; Parkinson Disease; Selegiline; Substantia Nigra; Vitamin E	1994
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? The Annals of pharmacotherapy, 1994, Volume: 28, Issue:3 Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline	1994
Antiparkinson efficacy of deprenyl. DATATOP Steering Committee of Parkinson Study Group. Annals of neurology, 1993, Volume: 34, Issue:4 Topics: Humans; Parkinson Disease; Placebos; Proportional Hazards Models; Selegiline; Survival Analysis	1993
Disturbance of colour perception in Parkinson's disease. Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 6, Issue:1 Topics: Adult; Aged; Color Perception; Color Perception Tests; Computers; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1993
Selegiline. Neurology, 1993, Volume: 43, Issue:12 Topics: Humans; Parkinson Disease; Selegiline	1993
[Parkinson disease: unusual treatments and perspectives]. Soins; la revue de reference infirmiere, 1993, Issue:572 Topics: Fetal Tissue Transplantation; Humans; Neurons; Parkinson Disease; Selegiline	1993
Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:3 Topics: Ascorbic Acid; Brain; Brain Neoplasms; Catecholamines; Cell Line; Drug Interactions; Female; Humans; Levodopa; Male; Neuroblastoma; Parkinson Disease; Quinones; Selegiline	1993
Treatment of Parkinson's disease. Neurology, 1993, Volume: 43, Issue:5 Topics: Antiparkinson Agents; Costs and Cost Analysis; Dementia; Humans; Parkinson Disease; Physical Therapy Modalities; Selegiline	1993
New mechanisms of action of irreversible monoamine oxidase type B inhibitors. Journal of psychiatry & neuroscience : JPN, 1993, Volume: 18, Issue:4 Topics: Brain; Central Nervous System Diseases; Dopamine; Female; Gene Expression; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1993
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology, 1993, Volume: 43, Issue:10 Topics: Aged; Antiparkinson Agents; Brain; Carbon Radioisotopes; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Picolinic Acids; Reference Values; Selegiline; Tomography, Emission-Computed	1993
End-of-dose dystonia in Parkinson's disease. Neurology, 1993, Volume: 43, Issue:10 Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome	1993
Protective effect of selegiline in the early and late phases of Parkinson's disease. Advances in neurology, 1993, Volume: 60 Topics: Age Factors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1993
Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clinical neuropharmacology, 1993, Volume: 16, Issue:1 Topics: Aged; Female; Humans; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Reaction Time; Selegiline; Time Factors	1993
When selegiline is prescribed, Stelazine may be mistakenly dispensed. Neurology, 1993, Volume: 43, Issue:1 Topics: Drug Prescriptions; Humans; Medication Errors; Parkinson Disease; Selegiline; Trifluoperazine	1993
Slowing of information processing in Parkinson's disease. Brain and cognition, 1993, Volume: 21, Issue:1 Topics: Aged; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Problem Solving; Reaction Time; Selegiline; Thinking	1993
Effect of selegiline on speech performance in Parkinson's disease. Folia phoniatrica, 1993, Volume: 45, Issue:1 Topics: Aged; Articulation Disorders; Humans; Male; Middle Aged; Parkinson Disease; Phonation; Pulmonary Ventilation; Selegiline; Speech Disorders; Speech Intelligibility; Speech Production Measurement	1993
Protective effect or symptomatic effect of deprenyl? The New England journal of medicine, 1993, Jun-10, Volume: 328, Issue:23 Topics: Free Radicals; Humans; Lipid Peroxidation; Parkinson Disease; Selegiline	1993
Speech dysfunction in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Dysarthria; Humans; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index; Voice Disorders	1995
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
Selegiline in Parkinson's disease. BMJ (Clinical research ed.), 1995, Dec-16, Volume: 311, Issue:7020 Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Failure; United Kingdom	1995
Failure of dopamine metabolism: borderlines of parkinsonism and dementia. Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 1995, Volume: 66, Issue:3-4 Topics: Antiparkinson Agents; Brain; Chronic Disease; Dementia; Dopamine; Humans; Neuropsychological Tests; Organotechnetium Compounds; Oximes; Parkinson Disease; Selegiline; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon	1995
Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice. Progress in brain research, 1995, Volume: 106 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Time Factors	1995
A 61-year-old man with Parkinson's disease. JAMA, 1996, Mar-06, Volume: 275, Issue:9 Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Meta-Analysis as Topic; Parkinson Disease; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Double-Blind Method; Levodopa; Parkinson Disease; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Research Design; Selegiline	1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation. BMJ (Clinical research ed.), 1996, Mar-16, Volume: 312, Issue:7032 Topics: Antiparkinson Agents; Cardiovascular Diseases; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Annals of neurology, 1996, Volume: 39, Issue:3 Topics: Antiparkinson Agents; Brain; Cytosol; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphocytes; Male; Middle Aged; Mitochondria; Parkinson Disease; Proteins; Selegiline; Superoxide Dismutase	1996
Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neuroscience letters, 1995, Nov-17, Volume: 200, Issue:2 Topics: Animals; Antiparkinson Agents; Cells, Cultured; Cerebrospinal Fluid; Culture Media; Dopamine; Female; Humans; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline	1995
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology, 1996, Volume: 46, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Cysteinyldopa; Humans; Levodopa; Malondialdehyde; Methoxyhydroxyphenylglycol; Middle Aged; Oxidative Stress; Parkinson Disease; Selegiline	1996
Parkinson's disease: consider pallidotomy as a therapeutic option. Geriatrics, 1996, Volume: 51, Issue:3 Topics: Globus Pallidus; Humans; Parkinson Disease; Selegiline; Stereotaxic Techniques; Treatment Outcome	1996
A 61-year-old man with Parkinson's disease. JAMA, 1996, Jul-10, Volume: 276, Issue:2 Topics: 1-Naphthylamine; Antidepressive Agents; Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline	1996
[Daily defined doses of parkinsonian drugs in Alcoi]. Revista de neurologia, 1996, Volume: 24, Issue:128 Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Utilization; Humans; Levodopa; Parkinson Disease; Selegiline; Spain	1996
Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease. Journal of the neurological sciences, 1995, Volume: 134, Issue:1-2 Topics: Aged; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors	1995
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease. Acta neurologica Scandinavica, 1995, Volume: 92, Issue:6 Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbolines; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Parkinson Disease; Selegiline	1995
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease]. Revue neurologique, 1996, Volume: 152, Issue:2 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Risk Factors; Selegiline	1996
Deprenyl's neuroprotective action remains unresolved. Annals of neurology, 1996, Volume: 40, Issue:2 Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline	1996
Deprenyl and levodopa and Parkinson's disease progression. Annals of neurology, 1996, Volume: 40, Issue:2 Topics: Antiparkinson Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Selegiline	1996
Deprenyl in Parkinson's disease. Annals of neurology, 1996, Volume: 40, Issue:2 Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1996
[The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease]. Terapevticheskii arkhiv, 1995, Volume: 67, Issue:10 Topics: Adult; Aged; Antiparkinson Agents; Chronic Disease; Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1995
Sensitive high-performance liquid chromatographic method for the determination of 2-phenylethylamine in human urine. Journal of chromatography. B, Biomedical applications, 1996, May-31, Volume: 681, Issue:1 Topics: Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Circadian Rhythm; Female; Humans; Indicators and Reagents; Linear Models; Male; Middle Aged; Monoamine Oxidase Inhibitors; o-Phthalaldehyde; Parkinson Disease; Phenethylamines; Psychotropic Drugs; Reproducibility of Results; Selegiline; Sensitivity and Specificity; Spectrometry, Fluorescence	1996
Multi-centre trials: U-turns by bandwagons and the patient left by the wayside. British journal of clinical pharmacology, 1996, Volume: 42, Issue:2 Topics: Antiparkinson Agents; Humans; Multicenter Studies as Topic; Parkinson Disease; Selegiline	1996
Pallidotomy in Parkinson's disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:10 Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Globus Pallidus; Humans; Levodopa; Motor Skills; Neurons; Parkinson Disease; Patient Selection; Selegiline	1996
Study design problems of DATATOP study analysis. Annals of neurology, 1996, Volume: 40, Issue:6 Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Selegiline; Vitamin E	1996
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease]. Revista medica de Chile, 1996, Volume: 124, Issue:3 Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking	1996
Selegiline and mortality in Parkinson's disease: another view. Annals of neurology, 1997, Volume: 41, Issue:2 Topics: Humans; Parkinson Disease; Selegiline	1997
Current therapy of Parkinson's disease. Iowa medicine : journal of the Iowa Medical Society, 1997, Volume: 87, Issue:1 Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Patient Selection; Selegiline	1997
Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Antiparkinson Agents; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	1996
Gallium-transferrin binding in treated and untreated Parkinson's disease. Neuroreport, 1997, Feb-10, Volume: 8, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Drug Therapy, Combination; Gallium; Humans; Levodopa; Middle Aged; Parkinson Disease; Protein Binding; Selegiline; Transferrin	1997
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology, 1997, Volume: 48, Issue:4 Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Central Nervous System Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Serotonin; Syndrome	1997
Treatment of Parkinson's disease: disagreements. Annals of neurology, 1997, Volume: 41, Issue:6 Topics: Disease Progression; Humans; Levodopa; Parkinson Disease; Selegiline	1997
Deprenyl, excess mortality, and epidemiological traps. Clinical neuropharmacology, 1997, Volume: 20, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1997
An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. Journal of neurochemistry, 1997, Volume: 69, Issue:1 Topics: Antioxidants; Apoptosis; Carcinogens; Catalase; Cycloheximide; DNA Damage; Dopamine; Free Radicals; Humans; Microscopy, Fluorescence; Neuroblastoma; Neuroprotective Agents; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Protein Synthesis Inhibitors; Salsoline Alkaloids; Selegiline; Semicarbazides; Stereoisomerism; Tetrahydroisoquinolines; Tumor Cells, Cultured	1997
Monoamine oxidase inhibitors and cardiac anesthesia revisited. Southern medical journal, 1997, Volume: 90, Issue:8 Topics: Aged; Anesthetics, General; Antiparkinson Agents; Coronary Artery Bypass; Drug Interactions; Hemodynamics; Humans; Male; Monoamine Oxidase Inhibitors; Narcotics; Parkinson Disease; Selegiline	1997
Unexpected findings of study of selegiline have not been treated with caution its authors advised. BMJ (Clinical research ed.), 1997, Aug-09, Volume: 315, Issue:7104 Topics: Antiparkinson Agents; Carboxy-Lyases; Humans; Levodopa; Parkinson Disease; Selegiline	1997
Selegiline and excess mortality. Clinical neuropharmacology, 1997, Volume: 20, Issue:6 Topics: Antiparkinson Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline	1997
Selegiline, pregnancy, and Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Adult; Antiparkinson Agents; Female; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Selegiline	1998
Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. The Journal of biological chemistry, 1998, Mar-06, Volume: 273, Issue:10 Topics: Animals; Antiparkinson Agents; Apoptosis; Biosensing Techniques; Brain; Cell Line; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Microscopy, Fluorescence; Molecular Structure; Muscles; Neuroblastoma; Neuroprotective Agents; Oligonucleotides, Antisense; Oxepins; Parkinson Disease; Photoaffinity Labels; Propylamines; Protein Binding; Rabbits; Rats; Selegiline	1998
[Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases]. Bulletin et memoires de l'Academie royale de medecine de Belgique, 1996, Volume: 151, Issue:10-11 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Parkinson Disease; Riluzole; Selegiline; Tacrine	1996
Parkinson's disease. Advance for nurse practitioners, 1998, Volume: 6, Issue:1 Topics: Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1998
Cortisol is higher in parkinsonism and associated with gait deficit. Acta neurologica Scandinavica, 1998, Volume: 97, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antiparkinson Agents; Constipation; Female; Gait; Humans; Hydrocortisone; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Risk Factors; Selegiline; Smoking	1998
Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be. BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139 Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	1998
Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early. BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139 Topics: Antiparkinson Agents; Bromocriptine; Decision Making; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline	1998
Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease. Journal of the neurological sciences, 1998, Feb-18, Volume: 155, Issue:1 Topics: Aged; Cyclic GMP; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1998
A frequency and correlation analysis of motor deficits in Parkinson patients. Disability and rehabilitation, 1998, Volume: 20, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prognosis; Psychomotor Disorders; Psychomotor Performance; Selegiline; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Time Factors	1998
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:2-3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline	1995
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 65, Issue:2 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver	1998
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 65, Issue:2 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver	1998
Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 1998, Volume: 105, Issue:4-5 Topics: Age of Onset; Aged; Antiparkinson Agents; Blood Proteins; Copper; Dopamine Agonists; Female; Humans; Iron; Levodopa; Male; Manganese; Metals, Heavy; Middle Aged; Nutritional Status; Parkinson Disease; Reference Values; Selegiline; Spectrophotometry, Atomic; Trace Elements; Vitamin A; Zinc	1998
Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease? Therapeutic drug monitoring, 1998, Volume: 20, Issue:6 Topics: Blood Platelets; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1998
Mortality cancer risk in parkinsonian patients: a population-based study. Neurology, 1999, Jan-15, Volume: 52, Issue:2 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Neoplasms; Parkinson Disease; Poisson Distribution; Retrospective Studies; Rome; Selegiline	1999
I2-imidazoline receptors in platelets of patients with Parkinson's disease and Alzheimer's type dementia. Annals of the New York Academy of Sciences, 1999, Jun-21, Volume: 881 Topics: Alzheimer Disease; Antiparkinson Agents; Blood Platelets; Cell Membrane; Humans; Idazoxan; Imidazoles; Imidazoline Receptors; Kinetics; Parkinson Disease; Receptors, Drug; Reference Values; Selegiline	1999
Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease. Neuroscience letters, 1999, Aug-13, Volume: 271, Issue:1 Topics: Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Selegiline; Thiamine; Thiamine Monophosphate; Thiamine Pyrophosphate	1999
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar. Geriatrics, 1999, Volume: 54, Issue:10 Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone	1999
Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate. Free radical biology & medicine, 1999, Volume: 27, Issue:9-10 Topics: 1-Methyl-4-phenylpyridinium; Allyl Compounds; Animals; Antioxidants; Butylamines; Corpus Striatum; Dopamine; Free Radical Scavengers; Hydroxybenzoates; Hydroxyl Radical; Hydroxylation; Injections, Intraperitoneal; Male; Microdialysis; Monoamine Oxidase Inhibitors; Neurotoxins; Parabens; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline	1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:6 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index	1999
Neuroprotection by (-)-deprenyl and related compounds. Mechanisms of ageing and development, 1999, Volume: 111, Issue:2-3 Topics: Aging; Amphetamines; Animals; Antioxidants; Apoptosis; Cattle; DNA Damage; DNA, Neoplasm; Indans; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Nitrates; Oxidants; Parkinson Disease; Selegiline; Tumor Cells, Cultured	1999
Altered redox state of platelet coenzyme Q10 in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:1 Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone	2000
A hypertensive reaction induced by concurrent use of selegiline and dopamine. The Annals of pharmacotherapy, 2000, Volume: 34, Issue:9 Topics: Aged; Blood Pressure; Dopamine; Heart Rate; Humans; Hypertension; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2000
Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds. Neurobiology (Budapest, Hungary), 2000, Volume: 8, Issue:1 Topics: Antioxidants; Antiparkinson Agents; Apoptosis; DNA Damage; DNA Fragmentation; Humans; Neurotoxins; Parkinson Disease; Salsoline Alkaloids; Selegiline; Structure-Activity Relationship; Tetrahydroisoquinolines; Tumor Cells, Cultured	2000
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Experimental neurology, 2000, Volume: 166, Issue:2 Topics: Alzheimer Disease; DNA Primers; Gene Expression Regulation, Enzymologic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Monocytes; Nerve Degeneration; Neuroblastoma; Neurons; Neurotoxins; Parkinson Disease; RNA, Messenger; Selegiline; Tumor Cells, Cultured	2000
Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. Journal of neurology, 2000, Volume: 247, Issue:10 Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interactions; Female; Humans; Middle Aged; Nortriptyline; Parkinson Disease; Selegiline; Serotonin Syndrome	2000
Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. Journal of neural transmission. Supplementum, 2000, Issue:58 Topics: Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dopamine; Enzyme Activation; Female; Humans; Male; Neuroprotective Agents; Oligopeptides; Parkinson Disease; Salsoline Alkaloids; Selegiline; Tetrahydroisoquinolines; Tumor Cells, Cultured	2000
Selegiline and Parkinson's disease: it's déjà vu-again. Neurology, 2000, Dec-26, Volume: 55, Issue:12 Topics: Humans; Parkinson Disease; Selegiline	2000
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology, 2000, Dec-26, Volume: 55, Issue:12 Topics: Aged; Aged, 80 and over; Cause of Death; Female; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Selegiline	2000
The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport, 2000, Dec-18, Volume: 11, Issue:18 Topics: Animals; Cell Survival; Cells, Cultured; Female; Fetus; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra	2000
[Dopaminergic agonists in the treatment of Parkinson's disease]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:6 Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles	2000
The economic consequences of a drug-drug interaction. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1 Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl	2001
Neurorescuing effects of the GAPDH ligand CGP 3466B. Journal of neural transmission. Supplementum, 2000, Issue:60 Topics: Animals; Animals, Newborn; Brain; Cell Survival; Cells, Cultured; Disease Models, Animal; Glyceraldehyde-3-Phosphate Dehydrogenases; Ligands; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Oxepins; Parkinson Disease; Rats; Rats, Wistar; Selegiline	2000
Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:4 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; Dopamine Agonists; Female; Humans; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	2000
Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adrenergic Agents; Apoptosis; Caspase 3; Caspases; Cell Survival; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Melanoma; Methamphetamine; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Proadifen; Selegiline; Tumor Cells, Cultured	2001
Freezing of gait in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline	2001
L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats. Neuroscience letters, 2001, Apr-20, Volume: 302, Issue:2-3 Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbolines; Cell Hypoxia; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Herbicides; Lactic Acid; Male; Microdialysis; Mitochondria; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Pargyline; Parkinson Disease; Rats; Rats, Wistar; Selegiline	2001
Advances in managing Parkinson's disease. Hospital practice (1995), 2001, Jun-15, Volume: 36, Issue:6 Topics: Activities of Daily Living; Algorithms; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	2001
[Parkinson patients. Normal life expectancy with selegiline?]. MMW Fortschritte der Medizin, 2001, May-28, Volume: 143 Suppl 2 Topics: Antiparkinson Agents; Follow-Up Studies; Humans; Life Expectancy; Parkinson Disease; Selegiline; Survival Rate	2001
Current advances in Parkinson's disease. Trends in neurosciences, 2001, Volume: 24, Issue:7 Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles	2001
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology, 2001, Jul-24, Volume: 57, Issue:2 Topics: Antiparkinson Agents; Humans; Longitudinal Studies; Parkinson Disease; Selegiline	2001
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology, 2001, Jul-24, Volume: 57, Issue:2 Topics: Antiparkinson Agents; Humans; Longitudinal Studies; Parkinson Disease; Selegiline	2001
Future of neuroprotection in Parkinson's disease. Parkinsonism & related disorders, 2001, Volume: 8, Issue:2 Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamine; Parkinson Disease; Propylamines; Salsoline Alkaloids; Selegiline; Tetrahydroisoquinolines; Tumor Cells, Cultured	2001
Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. Journal of neurology, 2001, Volume: 248, Issue:6 Topics: Acute Disease; Humans; Hypertension; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2001
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:11 Topics: Antiparkinson Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Parkinson Disease; Recombinant Proteins; Saccharomyces cerevisiae; Selegiline	2001
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl. Clinical and experimental neurology, 1979, Volume: 16 Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1979
2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]. Biochemical Society transactions, 1979, Volume: 7, Issue:1 Topics: Amphetamine; Brain; Humans; Parkinson Disease; Phenethylamines; Selegiline; Tissue Distribution	1979
Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. Advances in biochemical psychopharmacology, 1978, Volume: 19 Topics: Brain; Dopamine; Humans; In Vitro Techniques; Male; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin	1978
The possible mechanisms of action of (-)deprenyl in Parkinson's disease. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Acetylcholine; Animals; Biogenic Amines; Biological Transport; Cats; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Muscle Contraction; Muscle, Smooth; Parkinson Disease; Phenethylamines; Rabbits; Rats; Selegiline	1978
Overview of present day treatment of Parkinson's disease. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Receptors, Dopamine; Selegiline	1978
Absence of "cheese effect" during deprenyl therapy: some recent studies. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Amphetamines; Animals; Blood Pressure; Humans; Intestines; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Substrate Specificity; Swine; Tyramine	1978
Long term treatment with L-deprenyl. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1978
Recent observations on the clinical pharmacology of (-)deprenyl. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors; Tyramine	1978
L-deprenyl treatment of on-off phenomena in Parkinson's disease. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid	1978
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Amphetamines; Brain; Humans; Parkinson Disease; Phenethylamines; Selegiline	1978
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology, 1992, Volume: 42, Issue:4 Suppl 4 Topics: Bromocriptine; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline	1992
Therapy of Parkinson's disease: are we at the end of the road? The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:6 Topics: Antiparkinson Agents; Dopamine Agents; Humans; India; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1992
Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. Journal of neural transmission. Parkinson's disease and dementia section, 1992, Volume: 4 Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Female; Humans; Lymphocytes; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Superoxide Dismutase	1992
[Selegine in Parkinson's disease--current status in research and therapy. 2nd Internation Congress of Movement Disorders. Munich, 23 June 1992]. Der Nervenarzt, 1992, Volume: 63, Issue:9 Suppl Topics: Humans; Parkinson Disease; Selegiline	1992
Potential fluoxetine-selegiline interaction. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:10 Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline	1992
Selegiline and manic behavior in Parkinson's disease. Archives of neurology, 1992, Volume: 49, Issue:12 Topics: Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline	1992
Combination therapy of parkinsonism with deprenyl. The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:6 Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; India; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Selegiline	1992
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Annals of neurology, 1992, Volume: 32, Issue:6 Topics: Humans; Models, Statistical; Parkinson Disease; Selegiline; Survival Analysis	1992
Drug information discrepancy. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992, Sep-01, Volume: 147, Issue:5 Topics: Advertising; Canada; Humans; Parkinson Disease; Selegiline	1992
Some new aspects of the effect of (-)deprenyl in Parkinson's disease--a retrospective study. Journal of neural transmission. Parkinson's disease and dementia section, 1992, Volume: 4, Issue:2 Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index	1992
Long-term experience with selegiline and levodopa in Parkinson's disease. Neurology, 1992, Volume: 42, Issue:4 Suppl 4 Topics: Aged; Humans; Levodopa; Longitudinal Studies; Middle Aged; Parkinson Disease; Selegiline	1992
Emerging perspectives in Parkinson's disease. Neurology, 1992, Volume: 42, Issue:4 Suppl 4 Topics: Animals; Humans; Levodopa; MPTP Poisoning; Neurology; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1992
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1992, Volume: 7, Issue:3 Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Lactates; Lactic Acid; Levodopa; Lisuride; Male; Middle Aged; Mitochondria; Oxygen Consumption; Parkinson Disease; Receptors, Dopamine; Selegiline	1992
Selegiline and nigral neurons. Neurology, 1992, Volume: 42, Issue:8 Topics: Humans; Neurons; Parkinson Disease; Selegiline; Substantia Nigra	1992
Severe adverse interaction between pethidine and selegiline. Lancet (London, England), 1991, Jan-26, Volume: 337, Issue:8735 Topics: Drug Administration Schedule; Drug Interactions; Humans; Male; Meperidine; Middle Aged; Parkinson Disease; Selegiline	1991
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid. Advances in neurology, 1990, Volume: 53 Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Selegiline	1990
Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl. Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:4 Topics: Humans; Levodopa; Lisuride; Nervous System; Parkinson Disease; Selegiline; Survival Analysis	1991
Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments. Clinical neuropharmacology, 1991, Volume: 14, Issue:6 Topics: Aged; Epidemiologic Methods; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; United States	1991
Experience with selegiline and levodopa in advanced Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1991
Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease. Journal of photochemistry and photobiology. B, Biology, 1991, Volume: 11, Issue:3-4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radicals; Lasers; Monoamine Oxidase; Oxygen; Pargyline; Parkinson Disease; Radiation-Sensitizing Agents; Selegiline	1991
Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months. Archives of neurology, 1991, Volume: 48, Issue:1 Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline	1991
Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology, 1991, Volume: 41, Issue:6 Topics: Aged; Aged, 80 and over; Cell Survival; Humans; Neurons; Parkinson Disease; Selegiline; Substantia Nigra	1991
Treating the progressive stages of Parkinson's disease. Postgraduate medicine, 1991, Volume: 90, Issue:1 Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline	1991
Selegiline (Eldepryl) for Parkinson's disease. The Western journal of medicine, 1991, Volume: 155, Issue:1 Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1991
[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease]. No to shinkei = Brain and nerve, 1991, Volume: 43, Issue:4 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Rotation; Selegiline	1991
Early therapy for Parkinson's disease. Archives of neurology, 1991, Volume: 48, Issue:10 Topics: Humans; Levodopa; Parkinson Disease; Selegiline	1991
Psychiatric effects of selegiline. Archives of neurology, 1991, Volume: 48, Issue:9 Topics: Adult; Female; Humans; Mental Disorders; Middle Aged; Parkinson Disease; Selegiline	1991
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity. Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:3 Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline	1991
[Monoamine oxidase inhibitors]. Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:9 Topics: Antidepressive Agents; Dementia; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1991
[Changes in lipid metabolism in patients with Parkinson disease after combined treatment with L-deprenil (iumex) and antiparkinson drugs]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1990, Volume: 90, Issue:12 Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Middle Aged; Parkinson Disease; Phospholipids; Selegiline	1990
New concepts in the treatment of Parkinson's disease. American family physician, 1990, Volume: 41, Issue:2 Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline	1990
Inhibition of human benzylamine oxidase (BzAO) by analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology letters, 1990, Volume: 54, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benzylamine Oxidase; Carbidopa; Dopamine Agents; Humans; Kinetics; Parkinson Disease; Selegiline	1990
From the National Institutes of Health. JAMA, 1990, Jan-05, Volume: 263, Issue:1 Topics: Aged; Astrocytoma; Autoimmune Diseases; Danazol; HIV-1; Humans; Middle Aged; Parkinson Disease; Phenethylamines; Pregnadienes; Selegiline; Thrombocytopenia; Virus Replication	1990
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clinical neuropharmacology, 1990, Volume: 13, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Psychomotor Performance; Selegiline	1990
Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. Journal of chromatography, 1990, Jan-19, Volume: 499 Topics: Animals; Chromatography; Female; Male; Parkinson Disease; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline	1990
Deprenyl for the treatment of early Parkinson's disease. The New England journal of medicine, 1990, May-24, Volume: 322, Issue:21 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1990
Parkinson's disease: can we influence progression? British journal of hospital medicine, 1990, Volume: 43, Issue:5 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1990
Many researchers, few clinicians, using drug that may slow, even prevent, Parkinson's. JAMA, 1990, Sep-05, Volume: 264, Issue:9 Topics: Humans; Parkinson Disease; Selegiline; Vitamin E	1990
Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology, 1990, Volume: 40, Issue:9 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1990
'New studies on Parkinson's disease drug'. British dental journal, 1990, Sep-22, Volume: 169, Issue:6 Topics: Humans; Parkinson Disease; Selegiline	1990
Possible interactions between deprenyl and prozac. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1990, Volume: 17, Issue:3 Topics: Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Parkinson Disease; Selegiline	1990
Early combination with deprenyl: a retrospective analysis. Advances in neurology, 1990, Volume: 53 Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Retrospective Studies; Selegiline	1990
"Stelazine" versus "selegiline"--a hazard in prescription writing. The New England journal of medicine, 1990, Dec-20, Volume: 323, Issue:25 Topics: Aged; Drug Prescriptions; Female; Humans; Male; Medication Errors; Parkinson Disease; Selegiline; Trifluoperazine	1990
Deprenyl and Parkinson's disease: new use for an old drug. Cleveland Clinic journal of medicine, 1990, Volume: 57, Issue:6 Topics: Humans; Parkinson Disease; Selegiline	1990
Progression of Parkinson's disease. BMJ (Clinical research ed.), 1990, Sep-01, Volume: 301, Issue:6749 Topics: Humans; Neurotoxins; Parkinson Disease; Prognosis; Selegiline; Time Factors	1990
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. Journal of neural transmission. Supplementum, 1990, Volume: 32 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Brain; Humans; In Vitro Techniques; Male; Mice; Monoamine Oxidase; Nervous System; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Inbred Strains; Selegiline; Vitamin E	1990
New drugs for Parkinson's disease. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1990, Volume: 22, Issue:4 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline	1990
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Journal of neurochemistry, 1986, Volume: 46, Issue:5 Topics: Aged; Amines; Brain; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Indans; Kynuramine; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tissue Distribution; Tranylcypromine	1986
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline	1989
Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. Journal of neural transmission. Parkinson's disease and dementia section, 1989, Volume: 1, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Dose-Response Relationship, Drug; Humans; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors	1989
FDA approves marketing of two drugs previously available under treatment IND regulations. Clinical pharmacy, 1989, Volume: 8, Issue:9 Topics: Acquired Immunodeficiency Syndrome; Drugs, Investigational; Ganciclovir; Humans; Parkinson Disease; Phenethylamines; Selegiline	1989
From the Food and Drug Administration. JAMA, 1989, Nov-10, Volume: 262, Issue:18 Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Protocols; Didanosine; Drug Evaluation; Humans; Parkinson Disease; Phenethylamines; Selegiline; United States; United States Food and Drug Administration	1989
[A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989]. La Revue du praticien, 1989, Oct-01, Volume: 39, Issue:22 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1989
New strategies in the treatment of Parkinson's disease. Symposium. Copenhagen, Denmark, January 26-27, 1989. Proceedings. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1989
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Selegiline in the treatment of Parkinson's disease--long term experience. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline	1989
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Pharmacokinetics and metabolism of selegiline. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Alzheimer Disease; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Hypersexuality with antiparkinsonian therapy. Clinical neuropharmacology, 1989, Volume: 12, Issue:5 Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors; Sexual Behavior	1989
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Advances in neurology, 1987, Volume: 45 Topics: Animals; Brain; Dopamine; Fluorescent Antibody Technique; Humans; Isoenzymes; Macaca fascicularis; Monoamine Oxidase; Neuroglia; Neurons; Norepinephrine; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Synaptic Transmission	1987
MPTP: clinical implications. Journal of neural transmission. Supplementum, 1986, Volume: 20 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline	1986
[Deprenyl as a co-adjuvant in the treatment of Parkinson disease]. Acta neurologica, 1986, Volume: 8, Issue:4 Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline	1986
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease? Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Arylsulfotransferase; Blood Platelets; Humans; Monoamine Oxidase; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Sulfurtransferases; Tomography, Emission-Computed	1986
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors	1986
The role of MAO-b inhibitors in the treatment of Parkinson's disease. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1986
(-)Deprenyl in the treatment of decompensated Parkinson's disease. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline	1986
(-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages. Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: Adult; Aged; Carboxy-Lyases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1986
[Therapeutic strategies and tactics in parkinsonism]. Wiener medizinische Wochenschrift (1946), 1986, Aug-31, Volume: 136, Issue:15-16 Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders	1986
[Medicamentous strategy for improving the quality of life in the senescence]. Wiener medizinische Wochenschrift. Supplement, 1986, Volume: 98 Topics: Aged; Catecholamines; Caudate Nucleus; Corpus Striatum; Depressive Disorder; Dopamine; Humans; Monoamine Oxidase; Neural Pathways; Neurons; Parkinson Disease; Phenethylamines; Quality of Life; Receptors, Dopamine; Selegiline; Sexual Behavior; Substantia Nigra	1986
Critical role of MAO inhibition in Parkinson's disease. Advances in neurology, 1987, Volume: 45 Topics: Acetylcholine; Animals; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Structure-Activity Relationship	1987
MAO type B inhibitors as adjunct to L-dopa therapy. Advances in neurology, 1987, Volume: 45 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine	1987
Current and future approaches to therapy. Advances in neurology, 1987, Volume: 45 Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline	1987
Parkinson's disease: current view. American family physician, 1987, Volume: 35, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Selegiline; Substantia Nigra; Tomography, Emission-Computed	1987
Parkinson's disease in the elderly: current management strategies. Geriatrics, 1987, Volume: 42, Issue:7 Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1987
[Use of iumeks in the combined therapy of parkinsonism patients ]. Vrachebnoe delo, 1987, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Drug Evaluation; Drug Therapy, Combination; Higher Nervous Activity; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Muscles; Parkinson Disease; Phenethylamines; Selegiline	1987
MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline	1987
Milestones in the development of modern Parkinson therapy. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan	1987
Selegiline in the early and late phases of Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Dihydroxyphenylalanine; Disability Evaluation; Humans; Parkinson Disease; Phenethylamines; Selegiline; Time Factors	1987
Experience with selegiline in the treatment of Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Disability Evaluation; Humans; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors	1987
R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: Adjuvants, Pharmaceutic; Disability Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Phenethylamines; Selegiline	1987
Selegiline and the prophylaxis of Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chemical Phenomena; Chemistry; Humans; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Tissue Distribution	1987
Parkinson's disease and PET tracer studies. Journal of neural transmission. Supplementum, 1988, Volume: 27 Topics: Animals; Carbon Radioisotopes; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Energy Metabolism; Fluorine Radioisotopes; Humans; Ligands; Nomifensine; Parkinson Disease; Receptors, Dopamine; Selegiline; Spiperone; Tomography, Emission-Computed	1988
L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice. Chinese medical journal, 1988, Volume: 101, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Enkephalin, Leucine; Enkephalin, Methionine; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism	1988
Drugs for parkinsonism. The Medical letter on drugs and therapeutics, 1988, Dec-16, Volume: 30, Issue:781 Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1988
Hypomania in a patient receiving deprenyl (selegiline) after adrenal-striatal implantation for Parkinson's disease. Clinical neuropharmacology, 1988, Volume: 11, Issue:6 Topics: Adrenal Medulla; Adult; Caudate Nucleus; Combined Modality Therapy; Female; Humans; Parkinson Disease; Phenethylamines; Selegiline; Transplantation, Autologous	1988
[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1988, Volume: 88, Issue:12 Topics: Adult; Antiparkinson Agents; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1988
Deprenyl in Parkinson disease: personal experience. Italian journal of neurological sciences, 1985, Volume: 6, Issue:2 Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1985
Practical therapeutics: advances in the management of Parkinson's disease. East African medical journal, 1985, Volume: 62, Issue:2 Topics: Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Phenethylamines; Selegiline	1985
Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. Acta neurologica, 1985, Volume: 7, Issue:5 Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1985